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Small intestinal submucosa (SIS) derived from porcine small intestine has been 
intensively studied for its capacity in repairing and regenerating wounded and 
dysfunctional tissues. However, SIS suffers from a large spectrum of heterogeneity in 
microarchitecture leading to inconsistent results.  The goal of this study is to modify an 
already existing SIS biomaterial with poly(lactide-co-glycolide) nanoparticles (PLGA 
NPs) for better tissue regeneration. 
Specifically, nanoparticles made from PLGA were introduced into the SIS with the 
intention of decreasing the heterogeneity and improving the regenerative capability of 
this biomaterial.  As determined by scanning electron microscopy and urea permeability, 
the optimum NP size was estimated to be between 200-500 nm.  The PLGA NPs 
embedded in the SIS reduced the permeability of SIS to urea by almost 2-fold and did not 
change the tensile properties of the modified SIS as compared to the native SIS. More 
importantly, PLGA NP modified SIS did not affect human microvascular endothelial 
cells (HMEC-1) morphology or adhesion, but actually enhanced their growth.  
These NPs were also used to deliver hyaluronic acid (HA) to enhance the angiogenic 
potential of SIS. Hyaluronic acid is an essential part of the extracellular matrix (ECM).  
HA in biomaterials has been shown to help improve tissue regeneration and enhance 
angiogenesis. To target optimal delivery of exogenous HA, an understanding of the 
expression of HA and its receptors in regenerated rat bladder was investigated. Our 
studies indicate that expression of HA and HA receptors, CD44 and LYVE-1, were not 





HA-PLGA NPs were formulated to reduce the porous structure of SIS. Elevated cell 
proliferation was observed in HMEC-1 cells treated with HA-PLGA NPs as well as in 
HA-PLGA modified SIS (HA-PLGA-SIS). The HA-PLGA-SIS exhibited significantly 
enhanced neo-vascularization in an in ovo chorioallantoic membrane (CAM) 
angiogenesis model.  The regenerative capability of the newly fabricated HA-PLGA-SIS 
was tested in a large animal bladder augmentation model. Bladders regenerated with HA-
PLGA-SIS had significantly higher vascular ingrowth as compared to unmodified SIS. 
Based on the consensus that angiogenesis is essential for tissue regeneration, HA-PLGA-






Organization of Thesis 
Chapter 1 presents a detailed literature review on the subject matter.  This chapter 
depicts the problem being addressed and discusses other research done in the field. 
Chapter 2 describes the modification of an already existing biomaterial, small 
intestinal submucosa (SIS), with biodegradable polymer nanoparticles. Commercially 
available latex beads were used to determine the optimal size of the polymer 
nanoparticles that needed to be manufactured. The modified biomaterial was tested for its 
ability to support and sustain cell growth. The effects of the modification on the 
mechanical and physical properties of the SIS were also tested. 
Chapter 3 describes the immunohistochemical staining for hyaluronic acid and its 
receptors in regenerated rat bladder augmented with SIS. These experiments showed how 
expression changed with different stages of the tissue regeneration as the wound healing 
process progressed. The understanding of this process was critical for the delivery 
timeline of exogenous hyaluronic acid to a biomaterial for the purpose of better tissue 
regeneration. 
 Chapter 4 describes how the biomaterial was modified with hyaluronic acid- polymer 
nanoparticles and the different characterization tests that were carried out. From in vitro 
experiments to large animal model studies, the HA-PLGA-SIS demonstrated its potential 
as the biomaterial to enhance tissue engineering. 





Chapter 1  Background 
 Organ transplantation is a very important medical procedure, saving hundreds of 
thousands of lives each year.   However, there is a severe shortage of donor tissues and 
organs, which is worsening every year given the aging population. Tissue engineering 
aiming at the construction of neo-tissues in vitro or in vivo has become an attractive 
alternative to organ transplantation.  Tissue engineering is defined as “an interdisciplinary 
field that applies the principles of engineering and life sciences towards the development 
of biological substitutes that aim to maintain, restore, or improve tissue function1.” Tissue 
engineering has generated many promising results.  The selection of biomaterials as 
scaffolds is a critical factor in determining the success of tissue regeneration in the field 
of tissue engineering.   
Tissue engineering in bladder regeneration 
The main function of the bladder is to store urine at a safe pressure for the kidneys to 
operate normally and empty it in an acceptable manner2. There are several conditions that 
can lead to bladder disorders and malfunction, some of which are trauma, inflammation, 
disease, radiation and cancer. Loss of bladder function can lead to renal failure and 
urinary tract infection2. Patients that undergo partial cystectomy require bladder tissue 
replacement to restore bladder function. Bladder reconstruction has been used as a 
surgical procedure for treating a wide range of congenital and acquired diseases3,4. 
When pharmacological treatment and intermittent catheterization fail, bladder 
augmentation is needed and involves removing the top portion of the bladder dome and 




eliminate any immune response. Today, cystoplasty using the ileum, colon, or stomach 
segments is the gold standard procedure for bladder augmentation2. Unfortunately, the 
use of gastrointestinal segments for bladder augmentation can lead to electrolyte 
imbalance, stone formation, excessive mucus production, urinary tract infection, bacterial 
colonization, and cancer.  Gurocak et al. did an excellent job providing a review of the 
current state of bladder augmentation technology5. The goal of having an off-the-shelf 
biomaterial with no complications has not yet been achieved. Hence, bladder wall 
replacement is one of the most challenging problems in urologic surgery.  
The major obstacle to advancing the field of urinary tract reconstruction and 
rehabilitation has been the availability of a biomaterial, either permanent or 
biodegradable, that will function as a suitable scaffold to allow the natural process of 
regeneration to occur. The ideal graft material would promote the development of a 
structurally intact low-pressure reservoir, serve as a scaffold for the healing and 
regeneration of the bladder wall, and ultimately be replaced by the host tissue. If a 
suitable exogenous graft material was available, the need for autogenous tissue and all of 
the negative consequences associated with it could be eliminated. Therefore, investigators 
continue to search for the proper scaffold and methodology that is necessary to regenerate 
tissue and maximally restore urinary tract function. Currently, two technologies involving 
tissue engineering for bladder regeneration and augmentation are being investigated.  
The first reconstructive technology, the in vivo or unseeded tissue engineering 
technique for bladder regeneration, employs xenogenic (derived from stomach, bladder 
and small intestine) or synthetic biodegradable, acellular matrices. Such tissue 




material into a host that will then function as a scaffold to allow the natural process of 
regeneration to occur. While this technology provides the scaffold for wound healing and 
tissue regeneration, it also requires the host to provide the tissue and proper environment 
for cell growth and tissue regeneration. There are two major obstacles for this unseeded 
tissue engineering technology for bladder regeneration. The first has been finding a 
biomaterial that will act as a suitable scaffold for this natural process to occur. Synthetic 
non-biodegradable biomaterials such as silicone, rubber, polytetrafluoroethylene and 
polypropylene have been unsuccessful because of mechanical failure, lithogenesis, or 
host-foreign body reactions6-8. 
As a consequence of failures with non-biodegradable materials, synthetic and natural 
biodegradable materials have been investigated that would allow the host bladder time for 
regeneration but then dissolve prior to the onset of any foreign body reaction. These 
materials have shown improvements over non-biodegradable materials. Xenogenic, 
collagen-rich biodegradable materials such as placenta, amnion and pericardium have 
been used with even more encouraging experimental results than studies employing non-
biodegradable synthetic materials. However, despite initial encouraging results, none of 
these materials has been found to be suitable for clinical use. It has been reported that 
bladders augmented with dura, peritoneum, placenta and fascia contracted over time, and 
that such tissue grafts failed to promote a complete bladder wall regeneration9. Synthetic 
biodegradable polymers such as polyglycolic acid (PGA), polylactic acid (PLA), or 
poly(lactide-co-glycolide) (PLGA) have also been studied for bladder augmentation due 




complications such as lithiasis formation, infections, graft rejection, extrusion, or failure 
to adequately regenerate a full bladder12.  
Optimal materials need to be developed to provide the “perfect” biomaterial for 
appropriate tissue regeneration. The creation of hybrid materials from synthetic and 
natural substrates is an emerging filed in tissue engineering. It combines the biologic 
activities of naturally derived materials with favorable properties of synthetic ones such 
as mechanical properties and consistent reproducibility. 
Therefore, the design of synthetic bioscaffolds has shifted from strictly using 
synthetic polymers to combining these polymers with other biomaterials and molecules to 
enhance tissue engineering. Nakanishi et al. showed that a PLGA mesh-collagen hybrid 
scaffold seeded with urothelial and smooth muscle cells can been used to reconstruct a 
three-dimensional urinary bladder wall13. Oh’s group incorporated calcium peroxide-
based oxygen generating particles into PLGA scaffolds and showed that this new material 
can extend cell viability under hypoxic conditions14. Even though scaffolds made with 
synthetic and natural components have shown promising regenerative results, we do not 
yet have an off-the-shelf biomaterial that has been optimized for tissue engineering. 
The second potential limitation of the unseeded tissue engineering technique for 
bladder regeneration is that the size of the graft may be limited to the size of area that 
needs regeneration, which can be quickly occupied with bladder cells from the remaining 
native bladder.  If the ratio of the size of the unseeded graft to the amount of remaining 
native bladder tissue becomes too large, the ability of the body to occupy the graft with 
smooth muscle and urothelial cells appears to be compromised. In the absence of quickly 




concern and poor clinical outcomes may result. Clearly a tissue graft material is desired 
which is non-immunogenic, not subject to gross shrinkage after implantation, and which 
promotes the growth of endogenous urinary bladder tissues having a urine impermeable 
cell layer and a functional smooth muscle cell layer. 
The second tissue reconstruction technology, the in vitro or seeded tissue engineering 
technique, utilizes biodegradable materials that serve as both a scaffold for the 
regeneration process to occur as well as cell-delivery vehicles. This technology involves 
initial harvesting of bladder tissue, such as from a biopsy from host native tissue, to 
establish primary cultures of bladder cells. Cilento et al. demonstrated that it is 
theoretically possible to expand a transitional epithelial strain to cover the area of an 
entire football field using this method of cell culture15. These cells are then seeded on a 
biodegradable membrane and, following a period of graft maturation, the in vitro created 
bladder graft is then transplanted back into the host for continuation of the regeneration 
process. Yoo et al16 and Oberpenning et al17 reported on the feasibility of dog bladder 
augmentation using allogenic bladder submucosa and polyglycolic acid polymers 
membranes seeded with urothelial and smooth muscle cells. This study demonstrated that 
transitional epithelium and smooth muscle cells could be harvested, grown and 
subsequently seeded on allogenic bladder submucosa for use as augmentation material. 
Urodynamically, the augmented bladder demonstrated increased capacity during this 
short-term study. Interestingly, the unseeded allogenic bladder submucosa also 
demonstrated the ability to increase bladder capacity; however, the gains in capacity were 




Recently in 2006, Atala et al. performed a study where seven patients, ages 4-19 
years old, had their bladders augmented with a bladder-shaped scaffold made of a 
composite of collagen and PGA seeded with patients’ urothelial and smooth muscle cells 
that have been grown in culture11. The follow-up period was 22-61 months (mean 46 
months). Bowel function returned promptly after surgery. No complications were 
observed. The engineered bladder showed an adequate structural architecture and 
phenotype. They concluded that collagen-PGA scaffolds seeded with cells obtained from 
the patients and wrapped with omentum could be used in patients needing cystoplasty. 
Studies such as these suggest that prior cell seeding of large bladder grafts may be 
necessary to obtain the best clinical outcome following bladder augmentation. 
Unfortunately, although the in vitro technique of tissue engineering has been shown to be 
feasible for both synthetic and xenogenic matrices, there is still a risk of obtaining 
unhealthy cells from the patients to put on the scaffold. Therefore, having a cell-seeded 
off-the-shelf biomaterial is not practically desirable. In the present study, we have 
decided to go with the unseeded technology and used small intestinal submucosa (SIS) as 
the scaffold of choice. 
Small intestinal submucosa in 
tissue engineering 
SIS is a xenogenic membrane 
harvested from porcine small 
intestine in which the tunica mucosa 
and the serosa muscularis are 




mechanically removed from the inner and outer intestine respectively,  producing a thin, 
translucent graft (0.1 mm wall thickness) composed mainly of the submucosal layer of 
the intestinal wall18 (Figure 1-1). The submucosal layer of animal intestine has an 
established background in surgery as gut suture. SIS has been used successfully to repair 
and replace a variety of tissues including  tendon19, arterial and venous tissues20,21, skin22, 
abdominal wall23 and bladder24,25 in various animal models from rodents26 to rabbits27 to 
dogs28.  SIS is one of the most thoroughly studied collagen-based naturally occurring 
biomaterials for urinary tract reconstruction including ureter, bladder, and urethra29-34. 
The tremendous success of SIS is attributed to the fact that SIS contains an endogenous  
mixture of active intrinsic growth factors35, cytokines, structural proteins, glycoproteins 
and proteoglycans36 that may assist in cell migration, cell to cell interaction, and cell 
growth and differentiation during the regenerative process37. 
Researchers have shown that SIS can successfully regenerate a functional bladder in 
animal models29-31.  When SIS was used for urinary bladder augmentations in the rat, 
rabbit, and dog models, it was demonstrated that the SIS functioned as a scaffold 
allowing the native bladder to remodel and regenerate itself.  Histologically, the 
regenerated bladder contained transitional epithelium, smooth muscle, as well as 
peripheral nerves and were indistinguishable from the normal bladder in long-term 
augmentation studies29,32. 
However, there have been contradicting results throughout the literature about the 
outcome results of SIS usage. Petter-Puchner et al showed that the SIS showed adverse 
effects when used for ventral hernia repair in rats38. These effects included severe local 




testing. They concluded that further investigation needed to be done before clinical use of 
SIS in hernia repair. On the other hand, in a 3-year follow-up study performed in seventy 
male patients, Ansaloni’s group compared SIS with polypropylene mesh for inguinal 
hernia repair39. They devised a scaling system to quantify the results and showed that 
using the SIS in a clinical trial was safe and effective.  
To date, SIS has been shown to be non-immunogenic in over 1,000 cross-species 
transplants and direct challenge testing, demonstrating the lack of immunogenicity 
thereof. Kropp et al. performed urinary bladder augmentation in a rat model using SIS, 
and showed that SIS functions as a scaffold that allows the native rat bladder to remodel 
and regenerate itself40. Histologically, the regenerated rat bladders contained all three 
layers of the bladder (urothelium, smooth muscle and serosa) and were indistinguishable 
from normal rat bladder at 11 months post-augmentation. In addition, in vitro 
contractility studies showed that strips of in vivo tissue engineered SIS-regenerated rat 
bladder had contractile properties and nerve regeneration that was similar to the normal 
rat bladder41. This was the first evidence that a functional bladder could be achieved with 
tissue engineering techniques using SIS. It also demonstrated that SIS was different from 
other biomaterials that have been studied in the past. Previously, no other material had 
shown the ability to promote the regenerative capacity of bladder tissue that SIS 
demonstrated in the small animal model. 
In spite of the advantages and success of the SIS, researchers could not produce 
consistent bladder regeneration despite using the same techniques. It is not fully 
understood what causes this inconsistency in regeneration. One possibility is variations in 




and publish that the regenerative property of SIS is location-dependent42.  Distal SIS hat 
is taken from the ileum close to the ileocecal valve shows consistently excellent 
regenerative properties.  On the other hand, SIS made from the proximal jejunum 
(proximal SIS) produces poor bladder regeneration with scar formation and graft 
shrinkage. That group also showed that the physical properties of SIS are also location-
dependent43. 
In addition, while all segments of small intestinal submucosa have been used to 
promote urinary bladder regeneration, multiple problems have been encountered with 
different small intestinal segments, including calcifications and graft shrinkage, and 
therefore unreliable and inconsistent results have been obtained in the experimental use 
of this material for bladder augmentation. However, no studies have previously been 
undertaken to determine if SIS can be modified to provide a uniform structure or 
modified to incorporate macromolecules that are important for tissue regeneration and 
thus enhance the tissue engineering process. 
As discussed earlier, SIS has limited regeneration capability especially in large size 
graft tissue. If the seeded technology is not desirable, then the unseeded technique must 
be improved. One approach is to enhance the angiogenic capability of the SIS. Therefore, 
there is a need within the tissue engineering field to identify new and improved tissue 
graft substrates that have a substantially uniform structure that can deliver 
macromolecules for enhanced angiogenic effect. These biomaterials have to enhance the 
regeneration process through angiogenesis and generate reliable and reproducible results, 




this study focused on modification of the SIS using poly(lactide-co-glycolide) 
nanoparticles to enhance the angiogenic potential and regenerative capability of the SIS. 
Poly(lactide-co-glycolide) nanoparticles for delivery of macromolecules 
Nanotechnology involves the formulation and manipulation of materials to create 
unique products with novel properties at the nanoscale level. Nanoparticles (NPs) are 
submicron-sized polymeric colloids, and have been designed to deliver biologic 
molecules of interest either encapsulated within or condensed/conjugated on the surface 
of the particles44. Synthetic polymers have been used for manufacturing nanoparticles. 
Nanoparticles made from PGA, PLA and their copolymers (PLGA) represents a new 
generation of delivery systems.  These synthetic biodegradable polymers are non-toxic, 
do not elicit an immune response, biocompatible, biodegradable, and are approved by the 
Food and Drug Administration (FDA) for clinical usages45.  Poly(lactide-co-glycolide) or 
PLGA is the most studied synthetic polymer based on the properties stated above. PLGA 
nanoparticles have been intensively investigated as potential carriers for macromolecules 
such as drugs46-50, genes51-56 and hormones57. They have been used as anti-cancer 
treatments58-60 and as diagnosis tools61. 
Nanoparticles are advantageous over larger systems because they operate at the size 
scale of proteins giving them the ability for cell interaction and communication through 
the nanoscale environment. They are small enough to be internalized into arteries46 or 
cells62 if needed. PLGA nanoparticles can improve the compatibility of macromolecules 
used for therapeutic purposes; and the release rates of the biological macromolecules can 




There are two methods to formulate NPs. The first is the “bottom up” method and the 
second is referred to as the “top down”. In the first procedure, the individual monomers 
or building blocks are precisely engineered and the nanoparticles are produced through 
self-assembly63,64. Very few researchers use this method for the manufacture of NPs. This 
process is tedious and time consuming which makes it uncommon and not preferred by 
nanoparticle scientists. 
In the “top down” method, as the name implies, the process starts with large sizes of 
polymer and gradually reducing the size using different physical/chemical techniques. 
This is the most common procedure used to make NPs. Different procedures are available 
to formulate PLGA NPs. Astete and Sabliov provide a detailed review covering this 
issue65. The physical characteristics of PLGA NPs (size, size distribution, morphology, 
zeta potential) are affected by the different manufacturing methods as well as synthesis 
parameters. Below is a brief description of the two common methods used. These 
methods apply to other polymers but we will focus on PLGA. 
Emulsion diffusion method: in this method, PLGA is dissolved in an organic solvent 
that should be partially miscible with water such as ethyl acetate66. The organic phase is 
emulsified with an aqueous solution containing a suitable surfactant such as polyvinyl 
alcohol (PVA) under continuous stirring. The diffusion of the organic solvent and the 
counter diffusion of water into the emulsion droplets is what cause the formation of the 
NPs67.  Many parameters affect the NPs size including: PLGA monomer ratio 
(PLA:PGA), PLGA concentration and molecular weight (MW), organic solvent used,  
viscosity, organic and aqueous phase ratios, temperature, mixing rate, surfactant used and 




This method is used for encapsulating hydrophobic compounds. It does not require 
high-energy consumption because it requires mild stirring. It does not use any toxic 
solvents. Common disadvantages include low entrapment efficiency of hydrophilic 
compounds (most drugs are hydrophilic), use of large volume of water for NPs 
formulation and large time of emulsion agitation. 
Emulsion evaporation method:
The o/w emulsion is used for the entrapment of hydrophobic components, whereas 
the w/o/w emulsion is used for hydrophilic components.  This method is widely used 
because it is easy to scale up. It uses non-toxic solvents. Additives can be used to reduce 
the NPs size.  The main drawback of this process is the use of high shear stress such as 
sonication. 
 this is the oldest method used to make NPs. PLGA is 
dissolved in an organic solvent such as chloroform or methylene chloride. The organic 
phase is poured into the aqueous phase containing a surfactant and emulsified under high 
shear stress. The final step involves the evaporation of the organic solvent under vacuum 
inducing the formation of NPs. This is referred to as the oil in water (o/w) emulsion68. 
The water in oil (w/o) emulsion requires pouring the aqueous phase into the organic 
phase containing a surfactant and emulsifying69. Both w/o and o/w are referred to as 
single emulsions. The water in oil in water (w/o/w), also called double emulsion, involves 
the same steps of making a w/o emulsion. An additional step is pouring that w/o emulsion 
in a large volume of water under high shear stress and evaporating the organic solvent 
under vacuum70. Parameters that need to be considered are PLGA concentration and 
MW, surfactant used, PLA:PGA ratio, organic to aqueous phases’ ratio, evaporation rate 




There is a lot of room for modification considering that many parameters, such as 
PLGA concentration, MW, monomer ratio and so forth, can affect the physical 
characteristics of the NPs. For example, changing the percentage of surfactant/stabilizer 
in the aqueous phase of the second emulsion affects the size of the nanoparticles. 
Changing the monomer ratio of PLA and PGA changes the degradation rate of the PLGA 
nanoparticles and hence affects the release rate of encapsulated molecules within the 
nanoparticles. For example, PGA is hydrophobic while PLA is hydrophilic. Therefore, 
the higher the PGA content in PLGA, the more hydrophobic the nanoparticles are and the 
slower is their degradation. The exception to that rule is the 50:50 ratio, which degrades 
the fastest. We chose to use the emulsion evaporation method to make NPs because it 
allows us to adjust the characteristics of the NPs.  
Angiogenesis in tissue repair and regeneration 
Angiogenesis, the formation of new blood vessels from pre-existing ones, is essential 
in tissue and organ regeneration to provide a continuous support of nutrients and oxygen 
as well as carrying away waste byproducts71.  Angiogenesis depends on the dynamic 
interactions between cytokines, the extracellular matrix (ECM), smooth muscle cells and 
endothelial cells.  Impaired angiogenesis leads to impaired wound healing72; and 
improved wound healing is observed after topical administration of growth factors, 
particularly angiogenic factors73. 
The formation of blood vessels during the embryologic stage, vasculogenesis and 
angiogenesis, are the responsible processes for building the adequate vasculature to 
transport oxygen and nutrients in normal and pathologic stages. Disruption of one of 




decades, tissue engineering has proposed strategies to generate tissues in the laboratory in 
order to replace lost or malfunctioning organs. This endeavor has been proven extremely 
challenging due to the inability of the vascular network to penetrate into deeper layers of 
the new tissue. It is well known that cells more than a few hundred microns from a blood 
vessel will not survive due to diffusion limitations. This inability to develop the 
appropriate vascular supply to in vitro generated tissues has led to in vitro generated 
tissues of limited size. 
The requirement of a rapid, complete and organized formation of a blood vascular 
network for successful wound healing and tissue regeneration has also been demonstrated 
in other clinical settings.  For example, free skin grafts survive only if they are placed in a 
healthy and vascularized stromal bed76.  A variety of strategies using allografts, 
collagens, and other biological scaffolds have been designed to enhance blood vessel 
ingrowth into the regenerating tissues77-81.  To improve angiogenesis for successful tissue 
regeneration, angiogenic factors such as vascular endothelial growth factor (VEGF)82 
have been genetically introduced into cells seeded onto biodegradable grafts to enhance 
host blood vessels ingrowth into engineered tissues. Exogenous HA has also been 
introduced into scaffolds and shown to enhance angiogenesis83. 
Angiogenesis has been widely studied in the context of several pathologies such as 
inflammation, tumor growth, rheumatoid arthritis, wound healing and diabetic 
retinopathy because in theory, manipulating the vascular growth could be an effective 
strategy to control these pathologies. Angiogenesis is controlled by angiogenic factors 
(AF), which are substances that participate in directing organ development, and to date 




factor (VEGF) family84-87, the fibroblast growth factor (FGF) family88, the transforming 
growth factor (TGF-α and TGF-ß)89, platelet derived growth factor (PDGF)90, tumor 
necrosis factor alpha (TNF-α)91,92, angiopoietins93-95, interleukins96, leptin97, and last but 
not least important, hyaluronic acid (HA) derivatives98.  
Oxygen and nutrients are necessary for the growth, maintenance and reproduction of 
cells, tissues and organs under normal or pathologic conditions. During wound healing 
and tissue regeneration, the delivery of oxygen and nutrients is of critical importance for 
rebuilding a given organ. Oxygen generating scaffolds have been shown to extend cell 
viability under hypoxic conditions14. These biomaterials may allow for increased cell 
survival while angiogenesis is being established.  
When it comes to studying a pro-angiogenic molecule for a specific application, it is 
hard to make a choice given the multiple angiogenic factors that have been identified so 
far and the vast array of research done to date. Would you pick one molecule of choice or 
a combination of two or more? Many molecules in our body have overlapping roles or 
signaling pathways. It is very difficult and sometimes nearly impossible to study the 
effect of a single factor in complete isolation of its environment. However, one thing is 
for sure, angiogenic factors are needed to stimulate new blood vessel formation, which in 
turn enhances tissue regeneration. 
The work carried out on VEGF, which is implicated in the differentiation, migration 
and proliferation of endothelial cells, is extensive including more than a thousand papers 
for the biology of this molecule99. This protein is recognized as one of the most potent 
AF and there are several isoforms; three of these, VEGF121, VEGF165 and VEGF189 are 




enhancing angiogenesis, results have been somewhat disappointing and there are still 
several drawbacks to be overcome. For instance, there is an uncertainty about which 
delivery route to take, the speed of administration and the appropriate dosage. 
Furthermore, it is very well known that VEGF is also a potent vascular permeabilizing 
factor hence the first name for VEGF was vascular permeability factor (VPF)84,100. The 
most common collateral effect seen in pathologic stages and clinical trials has been the 
increase of blood vessel permeability101,102, which leads to fluid and proteins 
extravasations (e.g., fibrin deposits) and edema formation103-105. On the other hand, 
endothelial cells are not the only cells stimulated by this cytokine; lymphatic vasculature 
has also been stimulated by members of the VEGF family106,107. These findings have 
triggered the search for new molecules as alternatives when angiogenesis induction is 
considered as a treatment. 
Hyaluronic acid 
Hyaluronic acid (hyaluronan, sodium hyaluronate, HA) is a member of the 
glycosaminoglycans (GAGs) family, which are found almost exclusively in animals and 
primarily used to give structural stability to the tissues. GAGs are a family of naturally 
occurring linear or branched, negatively charged polymers. Other members of this family 
include dermatan sulfate, chondroitin sulfate, heparan sulfate, heparin, and keratan 
sulfate. HA is the only member of this family that is found non-sulphated, and not 
covalently bound to proteins. It has a molecular weight that ranges from 412 Da to 2×104 
kDa. HA is a natural polysaccharide composed of alternating (1 → 4)-β linked 











HA was first identified when Meyer and Palmer isolated it from the vitreous humor of 
bovine eyes in 1934108. The name was derived from hyalos, which is Greek for vitreous. 
In mammals, It is found in heart valves, skeletal tissue, umbilical cord, vitreous of the 
eye, synovial fluid and skin109. It is also an important part of the ECM because of its large 
molecular weight-space filling feature110. This large molecule is negatively charged 
hence attracting positive ions creating an osmotic imbalance that draws in water. HA has 
the capacity of binding huge amounts of water almost one thousand times its own weight 
giving it the ability to function as a biological lubricant in joints109. Table 1-1 shows 
common abundances of HA in animal tissues110.  
HA synthesis in the body is carried out by membrane-bound HA synthases (HAS), 
namely HAS1, HAS2 and HAS3. HA is unique among matrix macromolecules because it 
is directly secreted into the ECM as it is synthesized by smooth muscle cells111. These 
synthases produce different chain length HA. HAS1 and HAS2 produce HA of 2×105-
2×106 Da, whereas HAS3 produces HA of 1×105-1×106 Da, although this can vary 
depending on cell type112. 
 





















1400-3600 The volume of SF increases under inflammatory 


















100 HA concentration is much higher around the cells 
that synthesize HA 
Rabbit brain 65 HA is supposed to reduce the probability of 
occurrence of brain tumors 
Rabbit heart 27 HA is a major constituent in the pathological matrix 




0.2-50 The low molar mass of this HA is explained by the 
preferential uptake of the larger molecules by the 
liver endothelial cells 
Human 
urine 
0.1-0.3 Urine is also an important source of hyalurodinase 
Human 
serum 
0.01-0.1 HA concentrations increase in serum from elderly 
people as well as in patients with rheumatoid 
arthritis and liver cirrhosis 
 
A wide range of cellular activities requires HA such as cell migration, cell-cell 
adhesion, cell differentiation113, cell proliferation114, morphogenesis115, inflammation116 
and angiogenesis117. HA has some unique viscoelastic and rheological properties that 




biomaterial for medical applications110. The biomedical applications of HA as Balazs 
states it are as follows118: 
1. Viscosurgery: protect delicate tissue and provide space during surgical 
manipulations such as eye surgery. 
2. Viscoaugmentation: fill and augment tissue spaces such as skin and vocal 
tissues. 
3. Viscoseparation: separate connective tissue to prevent adhesions and scar 
formations during wound healing. 
4. Viscosupplementation: replace tissue fluids such as synovial fluid and relieve 
pain. 
HA is degraded by a group of enzymes called hyalurodinases (HYALs)109. These 
enzymes degrade the (1 → 4)-β linkage between N-acetyl glucosamine and glucouronic 
acid. There are six hyalurodinases: HYAL1-4, PH20 and HYALP1109. HYAL1 is the 
major hyalurodinase in plasma and urine that degrades HA extracellularly because it is 
active at physiologic pH119. HYAL2 is a cell surface enzyme that degrades only high 
molecular weight HA to fragments about 20 kDa, which are further degraded into smaller 
fragments by PH20109. PH20 is important during egg fertilization by sperm as it is located 
on the surface of sperm119. HYAL3 expresses in testis sand bone marrow and has no 
hyalurodinase activity109. HYAL4 is restricted to placenta and skeletal muscle and similar 
to HYAL3 has no hyalurodinase activity119. Not much is known about HYALP1. 
HA has been intensively studied for its involvement in wound healing processes.  HA 
has been shown to modulate inflammatory responses in several ways to reduce scarring 




influencing both the amount and nature of collagen production, and forming a matrix that 
binds protein inhibitors of serine proteinases such as plasmin, cathepsin G, and activators 
of matrix metalloproteinases111. Below is a summary of the biological effects of HA in 
the wound healing process (Table 1-2)111. 
Table 1-2 Biological functions of HA in the wound healing process 
Stage Process Mechanism 










Enhancement of cell infiltration 
Increase of pro-inflammatory 
cytokines TNF-α, IL-1β and IL-8 via 
a CD44 mediated mechanism 
Facilitates primary adhesion of 
cytokine-activated lymphocytes to 
endothelium 
 
Free radical scavenging and 
antioxidant properties 
TSG-6 and IαI mediated inhibition of 
inflammatory proteinases 











HA synthesis facilitates cell 
detachment and mitosis 
 
Increased HA synthesis 
HA-rich granulation tissue provides 
open, hydrated matrix that facilitates 
cell migration 
Receptor mediated cell migration, e.g. 
CD44, RHAMM 
 




HA-rich matrix is associated with 
proliferating basal keratinocytes 
Facilitates keratinocyte migration via 
a CD44 mediated mechanism 
Remodeling Scarring HA-rich matrix may reduce collagen 
deposition, leading to reduced 






Delivery of exogenous HA has been shown to produce beneficial wound healing 
outcome. Application of HA topically on rat skin wounds have shown to accelerate the 
wound healing process120. It is believed HA has a major effect on events leading to the 
fetal scarless wound healing121. HA content in fetal wounds remains higher and for 
prolonged periods of time compared to adult wounds suggesting HA’s role in reducing 
collagen deposition and hence reducing scarring122. This is in agreement with the work of 
Laurent et al. who showed that applying HA to tympanic membranes of rats resulted in 
scarless wound healing123. 
HA’s complete lack of immunogenicity, widespread availability and ease of chain 
size manipulation make it an ideal material for designing novel drug delivery systems.  
HA-based or HA-hybrid scaffolds have been applied in the field of tissue engineering and 
have been shown to be promising biomaterials for improving angiogenesis  and tissue 
regeneration124,125.  HA is also an FDA approved product for clinical applications to 
improve organ repair and function as well as for cosmetic applications.  
When fractionated by enzymatic digestion with hyalurodinase, fragments in the range 
of 4 to 24 disaccharides were shown to be angiogenic on the chorioallantoic membrane 
(CAM) model98. This study exposed the possibility of a dual effect of HA on blood vessel 
formation: long chains are anti-angiogenic whereas small fragments are pro-
angiogenic126. Table 1-3 lists some of the size-related functions of HA127. Other studies 
have shown similar conflicting results; for instance, oligosaccharides of HA (o-HA), 
were implicated in angiogenesis when wound-drainage fluid obtained from healthy and 
pathologic humans were tested for blood vessel development on the CAM model. The 




processing was rich in high MW HA and did not show any changes. On the other hand, 
when the extracted fluid was treated with hyalurodinase, which degrades HA into smaller 
fragments or o-HA, neovascularization was observed. This confirmed the opposite effects 
of different sizes of  HA in the wound extract128-130. 
Table 1-3 Sizes of HA with key functions 
Size (saccharides) Function 
Native or high MW 
(HA>1000-5000) 
Suppression of angiogenesis 
Immune suppression 
Inhibition of phagocytosis 
Suppression of HA synthesis 
HA fragments 
(~ 1000) 
Induction of inflammatory chemokines 
Stimulation of PAI-1 
Stimulation of urokinase 
10-40 Induction of CD44 cleavage 
Promotion of tumor cell migration 
8-32 Stimulation of angiogenesis 
Stimulation of tumor neovascularization 
~ 15 Suppression of smooth muscle cell proliferation 
12 Endothelial cell differentiation 
Upregulation of PTEN in tumor cells 
10 Displacement of matrix HA on oocyte surface 
Displacement of proteoglycans from cell surface 
6 Suppressions of HA cable formation 
Induction of NO and MMPs in chondrocytes 
Induction of HAS2 in chondrocytes 
4-6 Induction of cytokine synthesis in dendritic cells 
Transcription of MMPs 
4 Upregulation of Hsp 72 expression 
Suppression of apoptosis 
Induction of chemotaxis 
Upregulation of heat shock factor-1 
Upregulation of Fas expression 





New effects have also been described for o-HA, including for example, that 
intermediate sizes of o-HA (80 to 120 kDa) are implicated in the modulation of 
inflammation and immunologic responses131,132 while sizes ranging from 2 to 3.5 kDa 
were found to cause apoptosis in some cancer cell lines133,134. This ubiquitous molecule 
has triggered the interest of researchers in several fields. For researchers in the oncology 
field, HA might be a molecule that can be used in the treatment of some types of cancer. 
For tissue engineers, it would be a means to create vasculature for tissue engineering 
purposes by blocking either the molecule or its receptors to control blood vessel 
development. 
Research studies have demonstrated five hyaluronic acid receptors: CD44 (Cluster of 
Differentiation 44) also called Pgp-1 and H-CAM; LYVE-1 (Lymphatic Vessel 
Endothelial Receptor 1); HARE (HA Receptor for Endocytosis), also called LEC (Liver 
Endothelial Cell receptor); VEGFR-3 (Vascular Endothelial Growth Factor Receptor 3), 
and RHAMM (Receptor for HA Mediated Motility), also called IHABP (Intracellular HA 
Binding Protein). CD 44 is the major receptor for HA135,136. It also binds ligands other 
than HA. The binding of HA to CD44 has been shown to be involved in cell-cell and cell-
ECM adhesion137 as well as cell motility, endocytic uptake of HA, intracellular 
degradation of HA and ECM remodeling138,139. Studies in CD44 knockout mice show 
reduced ability to undergo normal would healing because of decreased cell migration, 
motility and ECM turnover112. 
The binding of HA to RHAMM is also involved in cell motility140. When the 
adhesion of HA to RHAMM has been blocked in mice, there was an inhibition of 




involved in the clearance of HA from the blood and lymph113,116. LYVE-1 is expressed in 
lymphatic endothelial cells that bind HA in ECM and lymphatic fluid. LYVE-1 is 
believed to be involved in the transport of HA from tissue to distant lymph nodes for 
degradation141,142. The binding of HA to VEGFR-3 is not fully understood. 
With this evidence, HA might provide significant assistance in developing a tissue 
engineering replacement of bladder sections using the PLGA NP modified SIS. We 
sought to deliver the HA to the SIS prior to in vivo experimentation by condensing the 
HA on the surface of the biodegradable PLGA NPs and gravity filter the whole complex 
(HA-PLGA NPs) through the SIS. 
The problem continues 
In summary, the SIS has shown great potential for tissue regeneration in many organs 
and tissues across multiple species. The SIS high permeability to urine and inability to 
support large size graft areas are still important issues that need to be addressed if clinical 
trials are to be conducted. We have sought to formulate PLGA NPs using the double 
emulsion technique and use these NPs to reduce the permeability of the SIS and as the 
delivery vehicle for HA. These HA-PLGA NPs are intended to modify the SIS and 
improve the angiogenic potential of this biomaterial through the continuous release of 
HA. The hypothesis is that if more blood vessels infiltrate the implanted tissue, the 
regeneration rate would improve, as nutrient mass transfer would be less limiting 
allowing  more cells to be recruited to the area. Therefore, improved angiogenesis needs 
to be addressed if optimal results for tissue engineering are desired. Further, we 
hypothesize that this approach can be accomplished using the aforementioned PLGA NPs 




Chapter 2 The incorporation of poly(lactide-co-glycolide) nanoparticles 
into porcine small intestinal submucosa biomaterials and its properties 
1. INTRODUCTION 
Small intestinal submucosa (SIS) derived from porcine small intestine has been 
intensively studied for its capacity in repairing and regenerating wounded and 
dysfunctional tissues.  However, SIS suffers from a large spectrum of heterogeneity in 
microarchitecture leading to inconsistent results.  In this study, we introduced 
poly(lactide-co-glycolide) nanoparticles (PLGA NPs) to SIS with an intention of 
decreasing the heterogeneity and improving the consistency of this biomaterial. This 
modification in the SIS physical properties was tested by studying the permeability of the 
PLGA NPs modified SIS to urea, a common nitrogenous waste product in urine. We also 
tested the effect of this modification on the mechanical properties of the SIS and 
investigated the influence of the new biomaterial on endothelial cell growth. 
2. MATERIALS AND METHODS 
2.1 Materials 
PLGA with a 50:50 monomer ratio, molecular weight of 106 kDa, and viscosity of 
1.05 dl/g was purchased from Absorbable Polymers International (Pelham, AL).  
Negatively charged polystyrene latex spheres (six sizes between 50 and 2,000 nm), urea, 
poly(vinyl alcohol) [PVA], poly(ethyleneimine) [PEI], and endothelial cell culture 
medium (MCDB-131) were obtained from Sigma-Aldrich (St. Louis, MO).  Single layer 
SIS (Surgisis®) was obtained from Cook® Biotech (West Lafayette, IN).  Chloroform was 




Diagnostics Chemicals Limited (Oxford, CT).  Fetal bovine serum (FBS) and penicillin-
streptomycin were obtained from Invitrogen (Carlsbad, CA).  Human microvascular 
endothelial cells (HMEC-1) were provided by Dr. Mike Ihnat at the University of 
Oklahoma Health Sciences Center143. 
2.2 Synthesis of PLGA NPs 
PLGA NPs were synthesized using a modified double emulsion solvent evaporation 
technique65.  Briefly, 30 mg of PLGA was first dissolved in 1 ml of chloroform.  An 
aliquot of 200 µl of 7% PEI (used to produce positively charge nanoparticles) was added 
to the PLGA/chloroform solution followed by sonication on ice with a probe sonicator 
(model VC60; Sonics & Materials, Danbury, CT) set in a continuous mode for 30 
seconds at 100% amplitude.  The primary emulsion was transferred into 10 ml of 1% 
PVA; and the entire solution was sonicated on ice for another 1 min.  The organic solvent 
in the final solution was allowed to evaporate overnight with continuous stirring.  PLGA 
NPs were recovered by centrifugation at 30,000 × g for 20 min at 4oC.  The pellet 
consisting of aggregated NPs was washed three times with water to remove any residual 
PVA.  PLGA NPs were then resuspended in water using sonication, freeze-dried and then 
stored at -20oC for later use. The lyophilized NPs are stable up to six months at -20oC. 
2.3 Characterization of PLGA NPs 
PLGA NPs were assessed for the particle size, polydispersity index, and zeta potential 
using diffraction light scattering Zeta PALS (Brookhaven Instruments, Holtsville, NY) at 
room temperature.  Viscosity and refraction indices were set equal to those specific of 
water.  Particle concentration was measured using a FACSCalibur flow cytometer 




water at four different concentrations.  Particle concentrations were calculated using a 
calibration curve developed using commercially available latex particles with four 
different known concentrations. 
2.4 Micro-architecture analysis of NP modified SIS 
 Lyophilized SIS was cut into 1.2 cm × 1.2 cm pieces and assembled in 1.5 ml 
Eppendorf tubes between the lid and the tube with mucosal side facing upwards (Figure 
2-1).  NPs were loaded onto the mucosal side of the SIS inserts.  The inserts were 
incubated overnight at room temperature with constant shaking on an orbital shaker.  To 
evaluate the micro-architecture of the NP modified SIS, the modified biomatrix was 
dehydrated using increasing concentrations of ethanol followed by a brief vacuum drying.  
Samples were then sputter coated with a 15 nm thick layer of gold at 40 mA and analyzed 
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2.5 Characterization of physical Properties of PLGA NP modified SIS  
SIS was made into long strips and fixed onto the inserts using silicone glue. PLGA 
NP suspensions with a concentration of 1.273 mg/ml were added onto the mucosal side 
of SIS.  The assembly was placed on an orbital shaker at 37°C overnight.  The NP 
modified SIS membranes were rinsed with water to remove unattached NPs.  The 
thickness of the NP modified SIS was measured using our previously described method43.  
Briefly, the NP modified SIS membranes were cut into small (2 mm × 10 mm) strips.  
Digital micrographs of the cross section were recorded using a Nikon inverted 
microscope (TE300) equipped with a CCD camera.  Cross section distances were 
measured using Sigma Scan Pro software (Systat Software Inc., Point Richmond, CA) 
which was calibrated using a grid image of a hemocytometer of known dimensions. 
Tensile properties were also determined by our previously described method43,144.  In 
brief, 6 cm × 1 cm strips of NP modified SIS membranes were cut from each sample and 
analyzed using an INSTRON 5842 (INSTRON Inc., Canton, MA) with a constant 
crosshead speed of 10 mm/min.  Tests were performed under hydrated conditions at 37ºC 
using a custom designed chamber. 
2.6 Urea permeability studies of NP modified SIS 
 Permeability was analyzed using the apparatus built in-house as shown in Figure 2-2.  
First, latex spheres or PLGA NPs were suspended in phosphate buffered saline (PBS, 
pH=7.4), and placed on the mucosal side of SIS in the custom-built apparatus in a way 
where gravity was the driving force (Figure 2-2A).  NPs were allowed to settle onto the 
SIS on an orbital shaker at 37oC overnight.  The NP modified SIS membranes were 




concentration in the human urine) in PBS.  PBS was then added to the serosal side of SIS 
in the second chamber and the apparatus was placed on its side (Figure 2-2B).  Aliquots 
of samples (20-50 µl) were collected from the second chamber every 10 minutes for one 
hour and at 2 hr.  The sample volumes were considered much smaller than the chamber 
volume (4 ml) and hence were not replaced. Samples collected immediately after the 
assembly of the chambers were used as time-zero values (i.e. C2 at t = 0).  Concentrations 
of urea were determined using a urea quantitation kit (Diagnostic Chemicals Limited, 






Figure 2-2 The custom-built chambers used in the study to measure urea permeability of modified SIS. A. 
The setup was used in this position to allow the latex spheres or PLGA NPs to go through the SIS under 
gravity. B. The permeability setup was used in this position to eliminate the role of gravity so that diffusion 
is the only driving force.  
 
 Membrane permeability was calculated as described previously43.  In brief, Fick’s 






Where D is the diffusion coefficient (in length2/time), C is the concentration (in 
amount/length3) and x is the diffusion distance (length). Fick’s second law of diffusion in 

































In order to solve this problem, the following assumptions are made: 
1. No chemical reaction takes place. 
2. The diffusion is one-dimensional. 
3. The diffusion is the only active force. 
4. The two chambers have equal volumes at all times. 
5. Quasi-steady state meaning the time it takes for the solute to diffuse through the 
membrane is much faster than the time it takes for the concentration to change on 




C .  







CD . Integrating this equation and using the 


















where C2 is the concentration of the urea measured at any time t in chamber 2, C0 (=550 
mM) is the initial concentration in chamber 1, Am is the membrane area (=π cm2 as the 
radius of the chamber is 1 cm), V is the volume of each chamber (= 4 ml), and P is the 









CC  was plotted as a function of time from 
which the slope (= V
PAm2  ) was determined using a linear fit.  The permeability was 






2.7 Evaluation of endothelial cell growth on PLGA NP modified SIS 
Cultured HMEC-1 cells were used to determine whether the PLGA NP modified SIS 
continued to support cell growth.  SIS was first assembled in Eppendorf tubes and placed 
in 24-well tissue culture plates as described previously145.  PLGA NPs were placed onto 
the mucosal side of the SIS as described above.  HMEC-1 were maintained in a complete 
growth medium (MCDB supplemented with 10% FBS and 1% penicillin-streptomycin) 
and were seeded at a density of 5.0 × 103 cells/cm2 on the mucosal side of the SIS.  To 
determine morphologies of HMEC-1 grown on the PLGA NP modified SIS, the cell-SIS 
constructs were stained with hematoxylin for 30 seconds, placed on a microscope slide, 
and sealed with an aqueous mounting media (Shandon, Pittsburg, PA).   
Genomic DNA contents were quantitated between 3 and 7 days following cell 
seeding to determine numbers of cells grown on NP modified and unmodified SIS. Both 
modified and native SIS were taken from the same SIS batch.  Briefly, cell composite SIS 
membranes were harvested by disassembling the SIS inserts and placing the composite in 
eppendorf tubes; cells were lysed with TNE buffer (10 mM Tris-HCl, pH 8.0, 150 mM 
NaCl, and 10 mM EDTA) supplemented with 0.2 mg/ml proteinase K (Invitrogen, 
Carlsbad, CA) at 55oC for 2 hours according to our reported procedure146.  Genomic 
DNA was subjected to phenol-chloroform extraction, ethanol precipitation, and resolved 
on 2% agarose gels.  Images of the genomic DNA were captured by a gel documentation 
system (Bio-Rad, Hercules, CA).  Genomic DNA band intensities were calculated using 
the Quantity One® image analysis software (Bio-Rad).  Genomic DNA isolated from 





2.8 Statistical analysis 
Data were expressed as means ± SD. Statistical differences between two groups were 
evaluated using Student’s t-test.  A statistical difference was considered significant when 
p<0.05. 
 
Figure 2-3 SEM images of latex spheres modified SIS.  Mucosal sides of SIS were imaged following 
overnight embedding of A. 2 µm, B. 1 µm, C. 500 nm, D. 300 nm, E. 200 nm and F. 50 nm latex spheres.  









3.1. Characteristics of synthesized NPs 
The average diameter of synthesized PLGA NPs was 242.0 ± 9.6 nm (n=5) as 
determined by dynamic light scattering (DLS). Polydispersity indices varied from batch 
to batch, but the average value was 0.148 ± 0.036.  The ζ potential (zeta potential) 
averaged +46.2 ± 3.4 mV.  The concentration assessment by flow cytometry indicated 
that 1 mg PLGA NPs suspended in 1 ml water generated an average of 1.62×108 
particles/ml. 
3.2. Surface structure of NP modified SIS 
 Commercial nominally monodisperse polystyrene latex spheres (sizes between 50 nm 
and 2 µm) were used to determine appropriate sizes of NPs to embed within SIS in order 
to reduce permeability to urea.  Latex spheres with diameters ranging between 200 and 
500 nm appeared on both mucosal and serosal sides of SIS (Figure 2-3C, C’, D, D’, E, 
E’).  In contrast, larger sizes (1 µm and 2 µm) of latex spheres were predominantly 
present on mucosal side of SIS (Figure 2-3A, A’, B & B’), whereas smaller size (50 nm) 
latex spheres were not observed on either side of SIS (Figure 2-3F & F’).  These results 
suggested that NPs smaller than 200 nm could not be retained in SIS and NPs larger than 
500 nm could not fit into the porous structure of SIS. 
 To determine whether PLGA NPs also possessed similar characteristics as latex 
spheres, two sizes of PLGA NPs (162 nm and 306 nm) at a concentration of 1 mg/ml 
were placed onto the SIS.  SEM images demonstrated that both sizes of PLGA NPs 
(Figure 2-4) went through the SIS similar to latex spheres.  However, less PLGA NPs 




to the serosal side (Figure 2-4B’).  Furthermore, more PLGA NPs with 306 nm in size 
were retained on the mucosal side (Figure 2-4C) relative to serosal side (Figure 2-4C’).  
Nevertheless, these results confirmed that NP sizes ranging between 200-500 nm would 
be appropriate to fit into the porous structure of SIS. 
Figure 2-4 SEM images of PLGA NP modified SIS. Unmodified SIS was imaged on A. mucosal side and 
A’. serosal side. B. Mucosal and B’. serosal sides of SIS modified with 162 nm PLGA NPs. Panels C and 
C’ show SIS modified by 306 nm PLGA NPs on mucosal and serosal sides of SIS respectively. 
3.3. Embedded NPs altered SIS permeability  
 NP modified SIS had reduced permeability to urea as compared to unmodified SIS 
(Figure 2-5A).  The permeability was 11.3 × 10-4 cm/s in unmodified SIS as compared to 
7.71 × 10-4 cm/s in SIS embedded with 200 nm latex sphere.  The permeability was 
reduced further to 6.53 × 10-4 cm/s when 300 nm latex spheres were used as compared to 
unmodified SIS.  Both 200 nm and 500 nm latex spheres reduced urea permeability even 
though the reduction was not statistically significant. There was no significant difference 
in permeability to urea between all three sizes (200, 300 and 500 nm). 
The permeability of the SIS to urea was then measured after introducing 260 nm 
PLGA NPs to SIS.  Three different concentrations, 0.1, 1.0, and 5.0 mg/ml of PLGA 




permeability was significantly reduced to 5.63 × 10-4 cm/s when 1.0 mg/ml PLGA NP 
was used to embed SIS as compared to either 0.1 or 5.0 mg/ml PLGA NPs (Figure 2-5B). 
 
 
Figure 2-5 Alteration of SIS permeability to urea by NPs. Permeability chambers were set up by placing A. 
latex spheres or B. PLGA NPs on the mucosal side of SIS to demonstrate size-dependent and concentration 
dependent permeability, respectively. Zero size or zero concentration indicates permeability measured with 
unmodified SIS and served as a control. Results are presented as means ± SD (n=3), where * indicates p < 
0.05 as compared to control. 
 
3.4. NP modified SIS did not alter mechanical properties of SIS 
To assess the effect of embedding NPs into SIS on mechanical property of SIS, 
tensile properties of PLGA NP modified and unmodified SIS were compared.  These 
results showed no significant difference in break stress or break strain (Figure 2-6).  In 
addition, when elastic modulus was calculated in the linear range (10 to 20% strain 
range), no significant difference was detected between NP modified SIS and native SIS 
(Table 2-1, n=12).  The elastic modulus of unmodified or native SIS was about the same 
compared to previous reports43.  However, the thickness of wet SIS in this study averaged 













Figure 2-6 Representative sample of a stress-strain curve of native SIS and PLGA NPs modified SIS. 
 
Table 2-1 Elastic properties of native and PLGA NPs modified SIS 
Sample Break-Point Stress (MPa) Young’s Modulus (MPa) 
Native SIS 4.12 ± 0.89 21.52 ± 4.02 
PLGA NPs SIS 4.24 ± 1.04 18.47 ± 4.23 
 
 
3.5. NP modified SIS supported cell growth 
HMEC-1 grown on both unmodified and NP modified SIS demonstrated similar 
morphological characteristics as shown in hematoxylin stained cell composite SIS 
constructs (Figure 2-7A).  As expected, HMEC-1 adhered and proliferated on unmodified 
SIS as determined by increasing quantities of genomic DNA contents between days 3 and 
7 after cell seeding (Figure 2-7B and C).  Although HMEC-1 cells adhered equally well 
on PLGA NP modified SIS as shown by similar genomic DNA contents between NP 
modified and unmodified SIS on day 3.  The number of HMEC-1 was 24,241 ± 3,298 on 




cell seeding; and the difference was statistically significant (p < 0.05) between 


















Figure 2-7 Endothelial cell growth on PLGA NP modified SIS. A. Representation of HMEC-1 cell 
adhesion on unmodified SIS and PLGA NP modified SIS. Arrows indicate the presence of cells in SIS 
structure. B. HMEC-1 proliferation on SIS as determined by genomic DNA contents was presented over a 
period of 7 days following cell seeding. C. Quantitation of HMEC-1 cell growth on native and modified 










SIS has been intensively investigated for its capability in tissue repair and 
regeneration in a variety of tissues and animal models in the last 20 years.  SIS has been 
shown to be a promising biomaterial for repair and regeneration in most applications due 
to its intrinsic ECM and growth factors35 that may promote cell migration, growth, and 
differentiation.  Numerous attempts have been made to produce “off-the-shelf” SIS 
products that would be available for clinical reconstructive surgical procedures25,40,147,148.  
However, SIS suffers from variations from batch to batch leading to different results in 
various applications.  These inconsistencies may result from heterogeneities of this 
biomaterial, since mechanical properties and regenerative capability of SIS depend upon 
species of animals, ages of animals, and locations of small intestine being used for SIS 
preparation43.  The goal of the present work was to introduce NPs to SIS in order to 
provide a consistent quality for this naturally derived biomaterial. 
The pores in the SIS are not uniformly distributed, nor are they uniform in size43.  
This explains the wide size ranges (200-500 nm) of particles capable of embedding 
themselves in SIS.   The absence of small size latex spheres (50 nm) within SIS in the 
SEM images may result from two reasons.  First, 50 nm latex particles may be too small 
to be retained in SIS in the SEM images; or, second, the 15 nm gold used for coating 
during SEM procedures may make the 50 nm particles difficult or impossible to be 
distinguished from the SIS.  It is also important to note that SIS differs from batch to 
batch from the same manufacturer.  For example, previously we reported Cook SIS 
thickness as 101 ± 19.84 µm (dry) and 246 ± 16.22 µm (wet)43.  In the present study, 




The permeability of SIS to urea was reduced with the embedding of the latex spheres 
within the SIS. That permeability to urea was reduced the most with the 300 nm latex 
spheres. This was evident also in the SEM images where fewer spheres were visible on 
the serosal side of the SIS and hence it could be inferred that more were utilized to plug 
the pores.  Permeability studies indicated that there was no significant difference in the 
measured urea permeability between the 200, 300 and 500 nm latex modified SIS. This is 
another indication of the heterogeneity of the pore sizes of the SIS. 
If we compare the SEM images for 162 nm and 306 nm PLGA NPs modified SIS in 
Figure 2-4, we can see more 162 nm PLGA on the serosal side of the SIS. This suggests 
that 306 nm PLGA NPs plugged more pores in the SIS than 162 nm NPs and thus fewer 
particles went through. This could also explain, why the 300 nm latex spheres reduced 
the permeability of the SIS to urea to a greater extent as compared to the other two sizes. 
It may also be possible to reduce the permeability of SIS further if a combination of 
different sizes of NPs is used for SIS modification. 
To determine the minimal concentration of PLGA NPs that can modify SIS, 260 nm 
PLGA NPs were used in urea permeability assays.  With 1 mg/ml PLGA NPs, the 
permeability was reduced significantly as compared to unmodified SIS.  The failure of a 
higher concentration, 5 mg/ml, to significantly reduce SIS permeability to urea might 
result from aggregation of PLGA NPs at higher concentrations. These aggregates would 
form large size NPs, probably too large to fit into the porous structure of SIS, and hence 
could not reduce SIS permeability similar to what was seen with larger sizes of latex 




The observation that PLGA NPs remained attached to or embedded within the SIS is 
very important especially if they will be used for delivery of therapeutics. It could take up 
to 16 weeks before the SIS is completely resorbed43 while the PLGA NPs (200 nm) will 
degrade in no more than 2 months65. This feature allows the NPs to remain attached to 
the SIS and deliver their load before the biomaterial is completely dissolved. 
Reduction in SIS permeability may be a critical factor in determining the success of 
tissue repair and regeneration especially in bladder regeneration.  Based on previous 
observation, proximal sections of SIS, that are more permeable to urea than distal 
sections of SIS43, have not been successful for bladder regeneration42.  The leakage of 
urine in augmented bladder can have detrimental effects on inflammatory responses 
during the process toward complete regeneration, and may result in the absence of 
bladder regeneration as we reported in a dog bladder augmentation model42.  We expect 
that the reduction in permeability in NP modified SIS will significantly improve tissue 
regeneration processes particularly in urinary bladder regeneration. 
The mechanical properties of the SIS stayed the same after modification with PLGA 
NPs. The reason the elasticity did not change in the modified SIS compared to native is 
that the elasticity is an inherent property of the collagen fibers within the SIS. Since the 
NPs were not embedded within the collagen fibers, we did not expect the elasticity to 
change. This is very important because we sought to change only the physical properties 
of the SIS and not the mechanical properties. Changing the mechanical properties might 
interfere with the cell-biomaterial interactions as well as with the compliance of the 
biomaterial, which might in turn effect the compliance of the tissue it is intended to 




The most significant observation was that PLGA NP modified SIS continued to 
support cell adhesion and growth. Since SIS interferes with various assay systems 
including colometric-based, fluorescence-based, and 3H-thymidine incorporation assays 
for determining cell proliferation, these assays are not appropriate for quantitating in vitro 
cell growth on SIS.  In this study, the number of cells growing on SIS were estimated by 
quantitating the amounts of extractible genomic DNA.  PLGA NP modified SIS did not 
interfere with HMEC-1 growth as demonstrated by the similar quantity of genomic DNA 
extracted from both unmodified and modified SIS on day 3. In addition, it is important to 
note that without cell adhesion there could be no growth. Therefore, even though a 
separate experiment was not conducted to test the effect of the modified SIS on cell 
adhesion, it is likely that PLGA NPs did not interfere with HMEC-1 adhesion to the SIS.  
HMEC-1 grew gradually on unmodified SIS between days 3 and 7 as we expected.  
Interestingly, HMEC-1 proliferation was significantly higher on PLGA NP modified SIS 
as compared to unmodified SIS on day 7.  The mechanism that is responsible for the 
enhanced cell proliferation in PLGA NP modified SIS is not clear.  The elevated cell 
proliferation might result from a uniform porous structure provided by NP modified SIS 
for easier cell migration and distribution, or synergistic effects of PLGA and SIS to 
support and enhance cell growth10,149,150. 
The continued growth of HMEC-1 cells on the modified SIS eliminates any concern 
about the effects of the degradation products of the PLGA NPs: lactic acid and glycolic 
acid on cellular functions.  One major concern of using PLGA NPs in tissue engineering 
is that these products might alter the microenvironments and interfere with cell 




In conclusion, PLGA NPs within a size range of 200-500 nm reduced the 
permeability of SIS to urea without interfering with the material’s mechanical properties. 
The PLGA modified SIS continued to support HMEC-1 growth, which was significantly 
enhanced by day 7 of cell culture, compared to native SIS. 
Future studies could address the possibility that a combination of different sizes of 
NPs could ultimately be needed to achieve maximal uniformity of SIS based on the 
variations of the SIS pore size as well as of the material from batch to batch.  
Another avenue that this study focused on was the use of PLGA NPs to deliver 
hyaluronic acid at the same time of being used to modify the SIS. The rationale for using 
hyaluronic acid was provided in Chapter 4. However, if the delivery of exogenous HA 
would be feasible, expression of HA and HA receptors in regenerated tissue need to be 
determined because HA works by binding to and activating its receptors. Delivery of HA 
to tissue may prove useless if there are no HA receptors in that tissue. The studies to 
determine the expression of HA and HA receptors in regenerating rat bladder were 




Chapter 3 Temporal Expression of Hyaluronic Acid and Hyaluronic 
Acid Receptors, CD44 and LYVE-1, in a Rat Bladder Regeneration 
Model Using Porcine Small Intestine Submucosa Scaffold 
1. INTRODUCTION 
Tissue engineering technology is intended to restore or replace aplastic, hypoplastic, 
or pathologic tissues or organs.  Reconstruction or replacement of abnormal bladder to 
restore bladder function is one of the most intensely studied applications in the field of 
tissue engineering.  Currently, two methods of bladder tissue engineering exist. The 
seeded technique involves harvesting host tissues to extract bladder cells (urothelial and 
smooth muscle) and culturing them to increase densities.  These cells are then seeded 
onto a biodegradable acellular matrix ex vivo and implanted into the host organ for 
continued regeneration processes11. An alternative to the seeded technology is the 
unseeded technique.  This technique involves implanting an acellular matrix, without 
prior cell seeding, directly into the host organ and allowing the host cells to repopulate 
the matrix and regenerate the tissue40. Both of these techniques have been shown to 
produce normal bladder tissue based on histological and functional criteria11,28,151. 
Hyaluronic acid (HA) is a non-sulfated glycosaminoglycan and an integral part of the 
extracellular matrix (ECM) widely distributed in connective, epithelial and neural tissues. 
It is a normal constituent of the basement membrane.  HA is composed of alternating (1 
→ 4)-β linked glucouronic acid and (1 → 3)-β linked N-acetyl-D-glucosamine.  HA 
mediates a wide range of cellular activities including  cell migration, cell-cell and cell-




well as angiogenesis113. HA has been studied in wound healing and tissue 
regeneration111,120. HA is believed to be actively involved in repair and regeneration 
processes based on its unique viscoelastic and rheological properties through binding to 
its receptors118. There are five HA receptors being identified currently, including CD44, 
LYVE-1, HARE, VEGFR-3 and RHAMM. 
In urinary bladder regeneration, HA has been incorporated into bioscaffolds to 
improve the outcomes of the regeneration process152,153. HA works by binding and 
activating its receptors. However, there is no report showing temporal and spatial 
distribution of HA and its receptors in regenerative bladder tissue. 
Small intestinal submucosa (SIS) harvested from porcine small intestine has the 
capability of promoting urinary bladder regeneration without cell seeding28,42.  Recent 
reports indicate that SIS derived from distal sections (300-400 cm proximal to the 
ileocecal valve) of porcine small intestine can promote complete regeneration in 
rodent154and canine bladder regeneration models42. This study was conducted to 
determine the temporal and spatial expression of HA and HA receptors in a SIS 
augmented rat urinary bladder regeneration model to determine if it would be 
physiologically relevant to deliver exogenous HA to the SIS.  
2. MATERIALS AND METHODS 
2.1 Reagents 
Peracetic acid, bovine serum albumin (BSA) and biotinylated hyaluronic acid binding 
protein (HABP) were obtained from Sigma-Aldrich Inc. (St. Louis, MO). Mouse anti-rat 
CD44 monoclonal antibody and rabbit anti-human polyclonal antibody VEGFR-3 were 




polyclonal antibody was obtained from Abcam (Cambridge, MA). Goat anti-human 
RHAMM polyclonal antibody was obtained from Santa Cruz (Santa Cruz, CA). Mouse 
anti-rat HARE monoclonal antibody was obtained from Dr. Paul Weigel (Department of 
Biochemistry and Molecular Biology, OUHSC). Goat serum and stable DAB 
(diaminobenzidine) were obtained from Invitrogen Inc. (Carlsbad, CA).  Fast red 
substrate was purchased from BioGenex (San Ramon, CA). Streptavidin-conjugated 
horseradish peroxidase (HRP) was obtained from Vector Laboratories Inc. (Burlingame, 
CA).  Streptavidin-conjugated alkaline phosphatase (AP) was obtained from BioLegend 
(San Diego, CA). Hematoxylin was obtained from Anapath Inc (Lewisville, TX).  
2.2 Animals   
Eighteen Sprague-Dawley adult female rats weighing 275-300 g were obtained from 
Charles River Laboratories (Raleigh, NC).  Three rats were used as surgical controls. The 
experimental animals were housed in the university animal care facility with free access 
to food, water and standard light/dark cycles.  Procedures used in this study have been 
approved by the Institutional Animal Care and Use Committee (IACUC). 
2.3 Preparation of SIS 
SIS was prepared from the distal segment of porcine ileum obtained from a 3-year old 
sow (from a slaughter facility, Weatherford, OK) as previously described154.  Briefly, the 
tunica mucosa and the serosa muscularis were mechanically removed. All segments with 
Peyer's patches were discarded.  SIS membranes were sterilized by exposing them to 
0.1% peracetic acid for 1 hour followed by three washes with sterile distilled water for 5 




digestive enzymes or solutions were used in the production of the SIS biomaterial. All 
experiments were performed using the same batch of SIS. 
2.4 Surgical procedures for bladder augmentation 
Rat bladder augmentation was performed using our previous reported procedure155.  
Briefly, rats were anesthetized by intraperitoneal injection of ketamine (100 mg/kg).  
Abdominal hair was clipped and the skin was prepped for sterile surgery.  A 3 cm 
midline abdominal incision was made and continued down to the peritoneal cavity.  An 
approximate 1 cm2 square area of the bladder dome was removed; and replaced with a 
similar sized SIS sutured to the native bladder margin using 6-0 Vicryl (Ethicon, 
Somerville, NJ) in a watertight fashion.  Permanent 6-0 Ethicon marking suture was used 
to determine the graft area. The abdominal wall was then closed.  The animals were then 
returned to normal housing. Three rats that did not have any surgical manipulation were 
used as unaltered controls. 
2.5 Tissue processing 
Rats were euthanized with lethal doses of pentobarbital on post-operative days 2, 7, 14, 
28, and 56.  There were three rats in each time group and three control rat bladders. The 
bladders were harvested, inflated with 10% formalin and fixed in 10% formalin for 24 
hours.  The bladders were then divided by a midline longitudinal incision and embedded 
in paraffin.  Paraffin sections were cut at 5 µm and mounted on glass slides, incubated at 







2.6 Immunohistochemical analysis 
Hematoxylin-eosin (H & E) staining was performed with an automatic slide stainer 
(Tissue-Tek DRS 2000; Sakura, Torrance, CA). For immunohistochemistry, the bladder 
sections were dewaxed in xylene, rehydrated in a series of graded alcohol, then in 
distilled water followed by rinses with 0.01M Tris-buffered saline (TBS) as previously 
described156.  Endogenous peroxidase activity was eliminated with the application of 
1.6% hydrogen peroxide in TBS for 30 minutes.  Tissue sections were incubated with 
TBS containing 10% goat serum and 1% bovine serum albumin (BSA) for 2 hours at 
room temperature to block non-specific binding.  To detect HA receptors’ expression, 
slides were then incubated with 1:400 mouse anti-rat CD44 antibody, 1:1200 rabbit anti-
human VEGFR-3 antibody, 1:800 rabbit anti-human LYVE-1 antibody, 1:400 goat anti-
human RHAMM antibody, or 1:2000 mouse anti-rat HARE antibody in TBS 
supplemented with 1% BSA.  A separate slide was incubated with the diluent without 
primary antibody and used as a negative control. Following rinses with TBS, the tissue 
sections were incubated with biotinylated goat anti-rabbit (VEGFR-3 and LYVE-1), 
biotinylated horse anti-mouse (CD44 and HARE), or biotinylated rabbit anti-goat 
(RHAMM) secondary antibody diluted to 1:400 with TBS with 1% BSA and incubated at 
room temperature for 2 hours. Following rinses with TBS, streptavidin-HRP (horseradish 
peroxidase) diluted to 1:400 with TBS and 1% BSA was added and incubated for 30 
minutes at room temperature followed by another rinse with TBS.  The bound antibodies 
were visualized by incubating the slides with stable 3,3’-diaminobenzidine (DAB) for 
four minutes.  The color development was terminated by washing the slides with tap 




tap water, dehydrated in graded alcohol, cleared in xylene, mounted with mounting 
medium, and cover slipped.  
For HA staining, slides were incubated with 1:200 1mg/ml biotinylated HABP for 2 
hours after blocking with 10% goat serum with 1% BSA. Following rinses with TBS, the 
tissue sections were incubated with 1:400 streptavidin-HRP and incubated at room 
temperature for 2 hours. HABP binding was visualized by incubating the slides with fast 
red for 20 minutes at room temperature. After washing with tap water, the slides were 
counterstained with hematoxylin for 20 sec, rinsed in tap water and mounted with 
aqueous mounting media. Microscopic images were taken with a Nikon Eclipse 80i 
(Nikon, Japan) microscope.  
2.7 Quantification of LYVE-1 positive lymphatic vessels 
Lymph vessels that stained positive for LYVE-1 in the augmented and native bladders 
were counted blindly. The results were reported as average ± standard deviation of 3 
animals in each time point. 
2.8 Statistical analysis 
Data were expressed as means ± SD. Statistical differences between two groups were 
evaluated using Student’s t-test.  A statistical difference was considered significant when 
p<0.05. 
3. RESULTS  
3.1. Inspection of bladder tissue regeneration 
Histological presentations of regenerated bladder were inspected by H & E staining of 
bladder tissues. Similar to prior studies, the SIS augmented bladder regeneration 




with hyperplastic changes and folding was evident by day 14 of the regeneration process 
(Figure 3-1).  By day 28, the urothelium layer (URO) was thinner and early fibroblasts 
were identified. A mature urothelium and smooth muscle layer was visualized at day 56 
as previously reported154. 
Figure 3-1 H & E staining of SIS-augmented rat bladders.  A. Native bladder for comparison. B-F. The 
graft portion of the augmented bladders. These augmented bladders were harvested on days 2, 7, 14, 28 and 
56 post-operation.  The suture materials (arrowhead) are identified and confirmed the site of operation.  
Urothelial (URO) covering is almost complete by day 14.  There is inflammatory cell infiltration in 
response to the surgery (small blue cells identified by the thin arrow) but inflammation is largely resolved 
by day 28. Regenerating smooth muscle fibers can also be identified in the regenerating site (thick arrow). 
Note the giant cell granuloma in response to the suture material located in the graft site (g). Original 








3.2. Temporal deposition and spatial distribution of HA 
The presence of HA in bladder tissues was detected by HABP through its specific 
binding to HA. There was no detectible HABP binding in control normal bladder. In the 
native and regenerating sections of the SIS augmented bladders, there was no HA binding 
activity up to 14 days post-operation.  In contrast, a strong HABP binding activity was 
observed in both the augmented and native portions of the regenerating bladders at days 
28 and 56 post-operation. The HA reactivity was mainly localized to the ECM of the 
connective tissues (Figure 3-2). 
 
Figure 3-2 Immunohistochemical staining for HA in the graft portion of the SIS-augmented rat bladders.  
A-E. HA immunoreactivity was determined on days 2-56 post-augmentation in SIS graft sections of 
regenerating bladders. The lumen of the bladder is indicated. F. Rat skin was stained in parallel and used as 
a positive control and tissue section digested with hyalurodinase was included as a negative control.  The 
expression of HA in ECM is evident in red. Original magnification: 4× in all panels. 
 
 
3.3. Temporal expression and spatial distribution of HA receptors 
CD44 
CD44 immunoreactivity in the regenerating bladders was minimal between day 2 and 14 




have increased. By day 56 post-operation, a strong CD44 immunoreactive signal was 
detected in bladder urothelial cells as well as in lymphocytes in the both the native and 
augmented portions of the regenerated bladders (Figure 3-3). 
 
Figure 3-3 Immunohistochemical staining for CD44 in the graft portion of the SIS-augmented rat bladders.  
A-E. CD44 immunoreactivity was determined on days 2-56 post-augmentation.  CD 44 immunoreactivity 
is mainly located in urothelium, and staining intensity increased as urothelial cells differentiated. In day 7 
(B), only a small amount of regenerating urothelium is present (arrow). A gradual increase in the 
immunoreactivity for CD44 is noted in the urothelium (URO) from day 14 to 56 (C-F). Original 






LYVE-1 immunoreactivity was not detected until day 28 (D28) and day 56 (D56) post-
augmentation (Figures 3-4A & B). The lymph vessels showed strong LYVE-1 
immunoreactivity in both the augmented and native sections of the bladders. There was 
also strong expression of LYVE-1 in the native bladder (Figure 3-4C). Quantitative 
analysis of LYVE-1 positive lymphatic vessels (n=3) showed that the augmented 
bladders at days 28 and 56 post-operation revealed 2.78 ± 1.56 lymph vessels /mm2 and 
1.95 ± 1.23 lymph vessels /mm2,  respectively (Figure 3-4D & Table 3-1). The native 
control bladder had 3.44 ± 0.06 lymph vessels /mm2. There was no expression of LYVE-
1 at the earlier time points, days 2, 7 and 14 (D2-D14). There was no statistical difference 
in number of lymphatic vessels between normal and augmented bladders according to 
Student’s t-test. 
VEGFR-3, RHAMM and HARE 
HARE immunoreactivity was weak and sometimes not evident in both native and 
augmented bladder tissues at all time points.  Commercially available primary antibodies 
against RHAMM and VEGFR-3 failed to demonstrate proper staining in rat bladder 
sections. 
 
Table 3-1 Quantification of lymph vessels in native and augmented rat bladder 
Sample Lymph vessels/mm2 (±SD) 
D28 SIS 2.78 ± 1.56 
D56 SIS 1.95 ± 1.23 









Figure 3-4 LYVE-1 immunoreactivity in SIS-augmented rat bladder.  Immunohistochemical staining of 
regenerating bladder on A. day 28 and B. day 56 post-augmentation.  C. Expression of LYVE-1 in native 
bladder is presented as a control. The expression of LYVE-1 in the lymph vessels is evident.  The 
endothelial cells of lymphatic vessels (LV) are immunoreactive but the endothelial cells of blood vessels 
(BV) are non-reactive. The red blood cells are indicated by the arrow. D. Lymph vessel counting was 
performed for all samples (n=3). There was no expression of LYVE-1 at earlier time points (D2-D14). 




HA plays an  important role in cell migration, proliferation, differentiation, 









HA is considered an important component for promoting wound healing and has been 
incorporated into bioscaffolds to improve the outcomes of tissue regeneration152,153.  
However, there is no data demonstrating whether HA is deposited in regenerating tissues 
endogenously or whether HA receptors are expressed at any phase of the regeneration 
process. This study represents the first characterization of HA and its receptors in a rat 
bladder regeneration model. 
We followed the expression of HA, as well as of CD44 and LYVE-1 during the 
process of wound healing and regeneration during the course of bladder regeneration.  
HA localization and HA receptor expression followed the same temporal pattern during 
the regeneration process.  As determined by immunoreactivity produced by HABP, HA is 
detected specifically in the ECM of both native and augmented portions of the 
regenerating bladder after 28 days post-operation, but not in control bladder.  This result 
is consistent with reports from skin wound healing157 and cancer development158 where 
results show an abundance of HA in the ECM.  In addition, Dechert et al. showed that a 
decline in the levels of HA occurred on the days that the inflammation was the highest, 
suggesting that HA levels in chronic wounds could be affected by inflammation159. The 
rat bladder augmentation model could be considered similar to a chronic wound model as 
inflammation persists on the early time points (days 2-14) and recedes on the later time 
points (days 28 and 56). This could explain the absence of HA in augmented rat bladder 
during the early phases of wound healing between days 2 and 14 and its presence on days 
28 and 56. However, there are clearly elevated levels of HA in regenerating tissue at 56 
days post-augmentation when the healing process has completed as indicated by the H&E 




and suggest that delivery of exogenous HA to chronic wounds may be preferred at later 
time points when inflammation have receded and more HA receptors are available. 
Although it would be highly informative to quantify the amount of HA present during 
the regeneration process, this was not feasible in the present study. One way to quantify 
HA in tissue is using western blot and an antibody specific to HA such as HA binding 
protein (HABP). However, the problem with this is when running gel electrophoresis, 
where the HA shows as a smear of bands instead of the typical one distinct band 
characteristic of proteins. This is because the common way of preparing HA of desired 
sizes is through digestion with hyalurodinase. This enzyme creates fragments of HA of 
multiple sizes. The desired size is simply the average, hence the smear of multiple bands 
in the gel. Another alternative way to quantitate HA is by using high performance liquid 
chromatography (HPLC). Unfortunately, we did not have access to such machinery. 
CD44 is a major receptor for HA. CD44 is widely expressed in epithelial, 
mesenchymal, and lymphoid cells in nearly all tissues142. CD44 has been shown to be 
involved in angiogenesis as CD44 knockout mice showed inhibition of vascularization in 
matrigel implants160. In this study, CD44 was mainly expressed in urothelial cells by day 
56 post-operation, which coincided with urothelial cell differentiation as previously 
reported154. Could there be a connection between CD44 and epithelial differentiation? 
Indeed there is, as Witt and Kasper showed in the development of taste buds that CD44 
expression appeared in the marginal epithelium cell membrane of early taste buds, and by 
late gestation and perinatally that expression has completely shifted to intragemmal cells, 
suggesting a role of CD44 in the differentiation of the taste bud cells161.  Yamazaki et al. 




did not occur strongly until day 21 of the fractured callus when the fracture was almost 
completely remodeled162. 
It is possible that accumulation of HA could be responsible for overexpression of 
CD44. At this point, we cannot determine the order in which HA or CD44 are expressed. 
Also, modulation of the HA-cell interaction during chondrogenic condensation in the 
embryonic chick limb parallels the expression initiation of CD44163. These findings 
demonstrated similar temporal appearance of HA and its major receptor, CD44, at day 28 
post-augmentation in this study. 
LYVE-1, cell surface HA receptor, shares similar structure with CD44 with different 
functionality142. LYVE-1 is expressed almost exclusively in endothelial cells of 
lymphatic vessels but not endothelial cells of blood vessels142. Consistently, we observed 
that LYVE-1 was exclusively localized to lymph vessel endothelium only in regenerating 
bladders.  Similar to the targeted expression of CD44 and HA, LYVE-1 was not detected 
in regenerated rat bladder until day 28 post-operation. The expression of LYVE-1 was 
strong both in the native and augmented parts of the bladder. We have previously shown 
that the inflammatory response in rat bladder augmented with SIS is most pronounced 
during the first two weeks of tissue regeneration155. By day 28, most of the inflammation 
has receded.  Expression of LYVE-1 can be regulated by inflammatory regulators164. 
Johnson et al. showed that incubation of pro-inflammatory cytokine tumor necrosis factor 
(TNF) with primary human dermal lymphatic endothelial cells (HDLEC) resulted in 
complete loss of LYVE-1 expression164. This may explain why LYVE-1 in lymph vessels 
was absent until day 28 when the inflammatory response was reduced. A similar 




very possible that accumulation of HA could be responsible for over expression of 
LYVE-1. At this point, it is not quite clear what is the mechanism behind the expression 
of these receptors. 
The goal of the present study was to determine temporal and spatial expression of HA 
in a regenerated tissue. Having HA receptors in the regenerated tissue is an important 
requirement for delivery of exogenous HA, which might prove useless if the receptors are 
not available. However, it was not clear from the IHC staining of LYVE-1 alone if any 
differences existed in the expression between days 28 and 56 post-augmentation. On the 
other hand, from the staining for HA and CD44, there was clearly more HA and CD 
immunoreactivity on day 56 post-augmentation. 
In conclusion, HA localization and expression of its receptors, CD44 and LYVE-1, 
show similar pattern of expression becoming evident at day 28 post-augmentation in rat 
bladder model. Delivery of exogenous HA to regenerated tissue is therefore a realistic 
avenue because of the presence of receptors that can bind and interact with HA. As 
discussed earlier, HA receptors were not present until day 28 post-augmentation. 
Therefore, delivery of exogenous HA could be established at later time points of the 
regeneration process when the proper receptors are available and inflammation has 
receded. However, we should not rule out the possibility that exogenous HA could be 
delivered at earlier time points. We do not know if elevated levels of HA could cause 
over expression of HA receptors although it is very possible. Based on his possibility, the 
delivery of HA to regenerated bladder could begin at the earlier time points of 




In Chapter 2 we have shown that PLGANPs modified SIS can improve endothelial 
cell growth while yielding more consistent outcome for regeneration. Therefore, the 
following studies, examining the delivery of HA to the SIS using PLGA NPs were 




Chapter 4 Enhanced angiogenic potential of porcine small intestine 
submucosa via hyaluronic acid-poly(lactide-co-glycolide) nanoparticles: 
From fabrication to pre-clinical validation 
1. Introduction 
Nanotechnology involves the formulation and manipulation of materials to create 
unique products with novel properties at the nanoscale level.  PLGA NPs are submicron-
sized colloids designed to deliver biologic molecules of interest either encapsulated 
within or condensed/conjugated on the surface of the particles44.  In this study, we 
explore the use of HA-PLGA treated biocompatible material (SIS) in tissue regeneration 
without cell seeding. 
HA is a major component of the extracellular matrix (ECM) and has been intensely 
studied for its roles in tissue development, wound healing, regeneration, tumor invasion 
and cell-cell interactions122,165,166.  HA-modified bioscaffolds have been investigated in 
the field of regenerative medicine to improve angiogenesis and tissue regeneration83,167. 
Identification of a biocompatible material is the first critical step in scaffold-induced 
tissue regeneration.  SIS has been investigated as a bioscaffold to repair and replace a 
variety of tissues. Unlike synthetic biomaterials, SIS supports cell ingrowth, 
differentiation, and tissue regeneration without prior cell seeding42.  However, the use of 
SIS in tissue engineering has been limited because of its inconsistency in supporting 
tissue regeneration for large areas168 and its location-dependency43. This deficiency is 
common in naturally derived biomaterials and likely contributes to the contradicting 




physical and biological properties of SIS could be modified using PLGA NPs while 
maintaining the structural integrity of the biomaterial. We also showed (Chapter 3) that 
HA and its receptors, CD44 and LYVE-1, are present in regenerating rat bladder. In this 
study, we sought to deliver HA using these PLGA NPs and study the effect of HA-PLGA 
NPs on endothelial cell growth and the angiogenic potential of the SIS modified with 
HA-PLGA NPs in in vitro CAM model and in vivo dog model. 
2. Materials and methods 
2.1. Reagents 
PLGA was purchased from Absorbable Polymers International (Pelham, AL) as a 50:50 
monomer ratio with molecular weight of 106 kDa and viscosity of 1.05 dL/g.  Hyaluronic 
acid with an average molecular weight of 74 kDa was purchased from Life core 
Biomedical (Chaska, MN).  Single layer SIS (Surgisis®) was provided by Cook® Biotech 
(West Lafayette, IN). Human mammary endothelial cells (HMEC-1) were provided by 
Dr. Mike Ihnat at the University of Oklahoma Health Sciences Center143. Fertile leghorn 
chicken eggs were purchased from CBT Farms (Chestertown, MD). 
2.2. Animals 
Fifteen adult male beagle dogs with an average weight of 14 kg were obtained from 
Ridglan Farms (Mt. Horeb, WI).  These animals were housed in the university animal 
care facility with free access to food, water and standard light/dark cycles.  All 
procedures for animal studies were in compliance with the Institutional Animal Care and 






2.3. Synthesis of HA-PLGA NPs 
PLGA NPs were synthesized using a double emulsion technique169 that was modified 
with polyethylene imine (PEI) to produce cationic NPs. Briefly, 30 mg of PLGA was first 
dissolved in 1 ml of chloroform.  An aliquot of 200 µl of 7% PEI was added to the 
PLGA/chloroform solution followed by sonication on ice with a probe sonicator for 30 
seconds.  The primary emulsion was transferred into 10 ml of 1% PVA; and the entire 
solution was sonicated on ice for another 1 min.  The organic solvent in the final solution 
was allowed to evaporate overnight with continuous stirring.  PLGA NPs were recovered 
by centrifugation at 30,000 × g for 20 min at 4oC.  The pellet was resuspended in water 
and freeze-dried for two days. A known amount of lyophilized PLGA NPs was 
resuspended in PBS pH 7.4 to get a 1 mg/ml stock solution. Different amounts of HA 
were mixed with a constant weight of 100 µg PLGA NPs to produce pre-determined w:w 
ratios and incubated at room temperature for 10 minutes. The HA-PLGA NPs were then 
centrifuged at 20,000 ×g at 4oC for 20 min.  The pellet was resuspended in PBS (pH 7.4) 
and centrifuged at 20,000 ×g at 4oC for 20 min three times to remove any unbound HA. 
The multiple washes were saved for later assay of HA. HA-PLGA NPs were finally 
resuspended in PBS (pH 7.4). The HA-PLGA NPs were prepared fresh for every 
experiment. 
2.4. Characterization of HA-PLGA NPs 
The size, polydispersity index, and zeta potential measurements of synthesized HA-
PLGA NPs were determined using diffraction light scattering Zeta PALS (Brookhaven 
Instruments, Holtsville, NY).  Viscosity and refraction indices were set equal to those 




scanning electron microscope (SEM). Loading efficiency was calculated using the 
following formula:  
 
 
2.5. Quantitation of HA incorporation and release 
The incorporated HA on the surface of the PLGA NPs was quantitated using an ELISA 
kit specific for HA (Corgenix, Broomfield, CO). To determine the release of HA from the 
PLGA NPs, 200 µl of these NPs were incubated at 37oC in PBS (pH 7.4) with continuous 
shaking at 750 rpm.  Aliquots of 100 µl were collected at 6 hours and days 1, 3, 7, 14, 21 
and 28 and centrifuged at 18,000 ×g for 20 minutes and quantitated using an ELISA kit to 
determine the sequential amounts of HA released over time. 
2.6. Endothelial cell proliferation assay 
To evaluate endothelial cell response to HA delivered by PLGA NPs, 600 µl of PLGA or 
HA-PLGA NPs were mixed with 80 µl collagen type I, 80 µl 10 × PBS and 2 µl 1N 
NaOH. Sterile double distilled H2O was added to the mixture to make a final volume of 
800 µl.  An aliquot of 50 µl of this mixture was delivered to each well of 96-well tissue 
culture plates and allowed to solidify at 37oC for 1 hour. HMEC-1 (1.0 × 103 cells) were 
distributed to each well in 100 µl of MCDB-131 medium supplemented with 10% FBS 
and 1% penicillin-streptomycin.  Wells that did not receive cells were used as the 
baseline control.  Number of viable cells was determined between days 3 and 7 using 


















2.7. Endothelial cell growth on HA-PLGA-SIS 
SIS and NP modified SIS were prepared in inserts as described previously145.  PLGA and 
HA-PLGA NPs were placed onto the mucosal side of SIS at a concentration of 1 mg/ml 
and incubated on an orbital shaker overnight.  HMEC-1 (5.0 × 103 cells/cm2) were seeded 
into the inserts; and cell-SIS membranes were harvested between days 3 and 7 after 
seeding.  Genomic DNA was isolated from these preparations using the same protocol as 
in Chapter 2.  Cell growth is indicated by the increasing amount of DNA extracted. 
Isolated genomic DNA was resolved on 1.2% agarose gels.  Images were captured by a 
gel documentation system (Bio-Rad, Hercules, CA).  Genomic DNA band intensities 
were calculated from the capture images using the Quantity One® image analysis 
software (Bio-Rad).  Genomic DNA from known numbers of HMEC-1 was used as a 
standard. 
2.8. Chicken embryo chorioallantoic membrane (CAM) vascular assay 
Fertilized eggs were incubated in a humidified incubator at 37.5oC for 7 days. A 2 cm 
hole was cut into the superior portion of the shell. Harris Micro Punch sections (1.2 mm) 
of SIS or NP-SIS were placed onto the CAM near large blood vessels. Antibiotic 
ointment was applied, holes in the shells were sealed by tape and the eggs were returned 
for continued incubation. The CAM was fixed in situ for 30 seconds using 4% w/v 
paraformaldehyde with 0.05% v/v triton X-100 after 4-day incubation. The CAM was 
excised and chorion was removed.   The CAM was then transferred to 6-well culture 
plates with 4% paraformaldehyde and the vasculature was imaged under a bright field 
microscope (Wild M400 Photomicroscope) connected to a digital camera (Retiga 1300, Q 




Imaging, Burnaby BC, CA) at 16× magnification and enhanced via Image J software 
(NIH). 
2.9. Evaluation of angiogenic property of HA-PLGA-SIS in a canine bladder model 
Drs. Christopher Roth and Yusuf Kibar (Department of Urology, OUHSC) performed the 
animal surgeries. Beagle dogs underwent hemicystectomy to remove the upper half of the 
urinary bladder per our established protocol28.  A piece of 8 cm × 8 cm of Cook SIS or 
SIS incubated with 1mg/ml HA-PLGA NPs w:w ratio of 0.5:1 (HA-PLGA-SIS) was used 
to cover the defect in a watertight fashion after the hemicystectomy. The dogs were 
euthanized 10 weeks post-operation. The augmented bladders were harvested, inflated 
with 10% formalin and fixed for 24 hours.  The bladders were divided longitudinally and 
embedded in paraffin.  Sections were cut at 5 µm for immunohistochemical analysis156. 
Mason’s trichrome was performed to show the structural architecture and phenotype of 
the tissue. CD31, a blood vessel endothelial marker, was utilized as a primary antibody 
followed by secondary incubation, chromagen development and light staining with 
hematoxylin. Total blood vessel count per unit area within the grafts was then 
determined. 
2.10. Statistical analysis 
Data were expressed as means ± SD. Statistical differences between multiple 
experimental groups were analyzed using single factor analysis of variance (ANOVA). If 
there were significant differences, Student’s t-test was used to evaluate the significance 







3.1. Characterization of HA-PLGA NPs 
The average diameter of synthesized PLGA NPs was 234.6 ± 8.2 nm (n=5) as determined 
by dynamic light scattering (DLS) (Figure 4-1A). The ζ potential (zeta potential) 
averaged +42.8 ± 4.3 mV.  After surface condensing of HA, the size of HA-PLGA NPs 
increased to 517.3 ± 6.3 nm (Figure 4-1B) and the zeta potential decreased to +7.79 ± 
0.63 mV (Table 4-1). This is critical because the change in ζ potential might interfere in 
the cell-NPs interaction as most cells are negatively charged. This change in ζ potential 
could also interfere in the stability of NPs in solution. The morphology and size of these 
NPs were verified with scanning electron microscopy (SEM) (Figures 4-1A & B). 
3.2.  HA release from HA-PLGA NPs 
HA released from the HA-PLGA NPs was measured between six hrs and 28 days using 
an ELISA-based quantitation assay.  A release rate, ranging from 8.9%/day to 17.6%/day 
was observed throughout the experimental period (Figure 4-1C).  By day 28, 81% of the 
loaded HA on the NPs had been released. The cumulative release is shown in Figure 4-
1D. Both types of release were measured as percentage of initial HA loaded on NPs. 
 
Table 4-1 Characterization of HA-PLGA nanoparticles 
Sample  Size (nm)  Polydispersity  Zeta Potential 
(mV)  
Loading 
Efficiency (%)  
PLGA NPs  241.9 ± 8.4  0.062 ± 0.005  + 34.67 ± 3.98  N/A  
HA-PLGA NPs 
(0.2:1)  
436.8 ± 8.5  0.160 ± 0.048  + 24.48 ± 2.08  15.5  
HA-PLGA NPs 
(0.5:1)  
490.3 ± 6.2  0.202 ± 0.012  + 19.43 ± 1.56  20.4  
HA-PLGA NPs 
(1:1)  





Figure 4-1 SEM of A. PLGA NPs and B. HA-PLGA NPs w:w ratio of 1:1.  C. Differential release of HA 
from HA-PLGA NPs over a period of 28 days (n=3). D. Cumulative release of HA from HA-PLGA NPs.  
The release was measured as percentage of initial HA loaded on the PLGA NPs. Measurements are 
reported here as means ± SD. 
 
 
3.3. Endothelial cell metabolic activity in response to HA-PLGA NPs 
Biological effects of HA-PLGA NPs were determined by measuring the metabolic 
activity of a human microvascular endothelial cell line, HMEC-1, using a XTT cell 
proliferation kit II (Figure 4-2). HA-PLGA NPs were synthesized using a constant 
amount of PLGA at 100 µg and varying the HA content to produce three w:w ratios of 
HA:PLGA (1:1, 0.5:1 and 0.2:1).  These HA-PLGA NPs were suspended in collagen gel 
PLGA NPs HA-PLGA NPs 






and plated into tissue culture plates followed by HMEC-1 cell addition.  HMEC-1 
responded to 1:1 ratio of HA:PLGA with rapid and significantly elevated metabolic 
activity, a 7.6-fold increase as compared to a 3.7-fold increase in PLGA NPs alone on 
day 5 after cell seeding (Figure 4-2).  No significant differences were observed on day 7 
probably because cells reached full confluence by then. This was expected because 


















Figure 4-2 Endothelial cell proliferation assay on collagen mixed with NPs and HA-PLGA NPs w:w ratios 
of 1:1, 0.5:1 and 0.2:1 (n=3). Measurements are reported here as means ± SD. * is where p=0.004 
compared to NPs. 
 
3.4. Endothelial cell proliferation on HA-PLGA-SIS 
Since SIS is incompatible with radioisotope incorporation, calorimetric assay, or 
fluorescent assay for measuring cell proliferation, HMEC-1 growth on HA-PLGA-SIS 
was quantitated by their genomic DNA contents as described before170 (Figure 4-3A).  




growth (8.7 × 104 cells) as compared to PLGA-SIS (6.2 × 104 cells) on day 7 following 
cell seeding (Figure 4-3B).  
 
Figure 4-3 Endothelial cell (EC) growth on the SIS modified with nanoparticles (n=3). A. Genomic DNA 
extractions at days 3, 5 and 7 from HMEC-1 grown on NP-SIS and HA-PLGA-SIS w:w ratios of 1:1, 0.5:1 
and 0.2:1. B. HMEC-1 proliferation on the groups mentioned above at different time points. Measurements 




3.5. Chorioallantoic membrane (CAM) angiogenesis assay analysis of HA-PLGA-SIS 
CAM has been used as an in vivo model to evaluate angiogenic capability of 
biomaterials171.  SIS, native and NP-modified, was placed on the CAM near major blood 
vessels (Figure 4-4A).  The total number of blood vessels was counted on images taken 
on day 5 following biomaterial placements.  An average of 45 vessels was observed for 
HA-PLGA-SIS with HA:PLGA at 1:1 ratio.  In contrast, averages of 35, 26 and 23 
blood vessels were observed in 0.5:1, 0.2:1 HA:PLGA ratios and PLGA NPs, 





PLGA-SIS (0.2:1) and PLGA-SIS.  Furthermore, averages of 15 and 9 blood vessels 
were observed with native SIS and cellulose nitrate, an inert membrane, respectively 
(Figure 4-4B). 
 
Figure 4-4 A. Effects of the different biomaterials Nitrate Cellulose, SIS, NP-SIS and HA-PLGA-SIS w:w 
ratios of 1:1, 0.5:1 and 0.2:1 on vascularization as determined by the CAM assay. The circle represents 
where the biomaterials were implanted. B. Blood vessels were counted manually for the different 
biomaterials (n=5). Measurements are reported here as means ± SD. * is where p<0.05. Original 
magnification: 16× in all panels. 
 
 
3.6. Improvement of angiogenesis using HA-PLGA-SIS in a canine bladder model 
To evaluate whether HA-PLGA modified SIS can improve angiogenesis in a tissue 
regeneration model, an established canine bladder augmentation model was used. In 
Chapter 3 we studied the expression of HA and its receptors in a regenerated rat bladder. 
The reason a dog bladder model is being used in this study instead because it is bigger 
than the rat bladder and hence will put to test the potential of the HA-PLGA modified SIS 





augmented with SIS or HA-PLGA-SIS [SIS incubated with HA:PLGA at 0.5:1 (w:w) 
ratio overnight on an orbital shaker] and harvested at 10 weeks for histological 
evaluation.  The 10-week time point was picked because the regeneration process has 
been shown to be completed by then in a previous study42. The reason the 0.5:1 
HA:PLGA w:w ratio was used,  instead of the 1:1 that showed the most significant effect 
in all in vitro and CAM studies, because the animal studies were performed before the in 
vitro studies were completed.  Mason’s trichrome showed the collagen fibers and smooth 
muscle bundles in both the graft and native tissues (Figures 4-5A & C).  The graft area 
was identified by the transition from mature smooth muscle bundles in the native tissue to 
smooth muscle cells and fibers.  HA-PLGA-SIS, in general, outperformed SIS in the 
overall quality of regenerated bladder based on the examination of the regenerated 
smooth muscle bundles and collagen fibers through Mason’s trichrome.  Angiogenesis of 
the graft tissues was determined by immunohistochemical staining with CD31 for 
endothelial cells (Figures 4-5B & D).  Quantitative measurements of CD31 
immunoreactive blood vessels demonstrated significantly more blood vessels observed in 
HA-PLGA-SIS (13.2 ± 3.9 vessels/mm2) as compared to SIS (6.6 ± 1.6 vessels/mm2) as 




Figure 4-5 Histopathology of the graft in canine urinary bladder was demonstrated by Masson’s trichrome 
stain in A. SIS  and C. HA-PLGA-SIS. Note the transition from mature detrusor muscle bundles (arrow, 
stained red) to developing smooth muscle fibers within the graft area (stained blue). Smaller regenerating 
muscle fibers are found in the collagenous tissue within the graft (inset). Immunohistochemistry for CD31 
was utilized to identify the endothelial cells of blood vessels in the same region in B. SIS and D. HA-
PLGA-SIS augmented canine bladder grafts. Blood vessel samples are enlarged in insets. E. Blood vessels 
were counted manually for the entire graft area (n=5). Measurements are reported here as means ± SD. * is 










We previously demonstrated that PLGA NPs incorporated into SIS reduced the 
permeability of the biomaterial to urea and enhanced endothelial cell proliferation 
without altering the mechanical structure of SIS (Chapter 2).  The reduction in urea 
permeability is particularly important for urinary bladder regeneration since urine leakage 
may represent a serious obstacle in bladder regeneration.  To utilize the biochemical 
properties of HA to enhance wound healing111 and angiogenesis172, HA was encapsulated 
onto PLGA NPs.   
The HA-PLGA NPs were then embedded into SIS to maintain a porous structure and 
provide a uniform architecture for consistent regenerative properties.  Even though cell 
metabolic activity is not a measure of cell growth, if we take into consideration the 
combined effect of the enhanced cell metabolic activity and increase in the genomic 
DNA, we can relate that to an increase in cell growth. The HA-PLGA-SIS not only 
promoted endothelial cell growth, but also enhanced angiogenesis in both CAM assay 
and in vivo canine bladder augmentation model. We concluded that HA-PLGA-modified 
SIS might overcome the heterogeneity of naturally derived biomaterials and promote the 
establishment of vascular networks crucial to rapid and complete tissue regeneration. 
PLGA NPs have several advantages over other delivery methods such as liposomes 
based on their stability, high encapsulation efficiency, and better control over the release 
of the encapsulated therapeutic molecules173 simply by controlling the monomer ratio, 
molecular weight as well as other parameters. In addition size, surface charge, 
hydrophilicity and degradation rate of NPs can be optimized65. The PLGA NPs were 




NPs.  This feature gives the NPs the unique ability to condense negatively charged 
molecules, such as HA, on their surface. The biodegradable characteristics of PLGA NPs 
make it feasible to deliver molecules of interest in moderate portions in a continuous 
mode without leaving any toxic byproducts.  Although PLGA NPs are small enough to be 
internalized into cells if needed70, giving them advantage over larger systems, HA was 
encapsulated outside of PLGA in this application so that cells expressing HA receptors 
can interact with the HA.  In other words, the HA did not need to be internalized inside 
the cells to have an effect. Most HA cell surface receptors are located on the cell 
membrane that constantly interact with the HA that is outside the cell in the ECM, for 
example. 
One might point to a concern that the HA-PLGA NPs with w:w ratio of 1:1 might be 
too big (517.3 nm from Table 4-1) to embed into the SIS and hence would not be able to 
reduce the permeability of the SIS to urea. We found earlier in Chapter 2 that 300 nm size 
spheres reduced the permeability of SIS to urea the most whereas 500 nm not so much. 
The reason there is a difference in diameter between the HA-PLGA NPs with w:w ratio 
of 1:1 in the SEM images (Figure 4-1B) and Table 4-1 is because the DLS measures the 
hydrodynamic diameters, which include the NPs as well as the water molecules 
surrounding the particles. The diameters obtained from the SEM, on the other hand are 
the “dry” diameters. Hence, the diameter measured by the DLS of a nanoparticle solution 
appeared to be bigger than that measured by SEM of a dry sample. The dry diameters of 
PLGA and HA-PLGA NPs were 156 nm and 328 nm, respectively. 
As mentioned earlier, the negatively charged HA was condensed on the surface of the 




that kept HA conjugated to the surface. HA is a linear polysaccharide however, in 
solution, HA has a secondary structure because of the hydrogen bonding making it 
behave as an expanded coil with diameter of 500 nm174. Trimm and Jennings showed that 
each disaccharide unit is almost equivalent to 1 nm175. HA below 500 kDa shows a rod-
like behavior and above that molecular weight behaves as a random coil175. In addition, 
X-ray diffraction of potassium hyaluronate fiber showed a left-handed 4-fold helix of 
axial rise 0.95 nm per disaccharide176. Therefore, we can say the 74 kDa HA (185 
disaccharide units) used in this study is roughly 185 nm in length. From the difference in 
SEM “dry” diameters between PLGA and HA-PLGA NPs we can say that the thickness 
of the HA layer around the PLGA NPs is about 172 nm. We propose the following 
mechanism of HA binding to the PLGA NPs. Similar to the binding of the negatively 
charged DNA to the positively charged histones, the HA could wrap around the PLGA 
NPs as a string wraps around a marble. However, unlike the DNA binding which is more 
organized, the binding of HA to PLGA could be random. Therefore, it could be very 
possible that the HA-PLGA binding may not completely follow the DNA-histone 
mechanism but may in fact be a combination of HA wrapping around the PLGA NPs as 
well as HA sticking outward. 
HA has been shown to play a critical role in cell growth and differentiation177 and to 
elicit angiogenic responses.  Angiogenic property of HA appears to be size related178.  
One of the unique features of HA is that native or high molecular weight HA can be 
enzymatically cleaved to produce fragment sizes of HA (oligo HA, o-HA)172 that are pro-
angiogenic.  In some cases, as in inflammation and angiogenesis, long (400-2000 kDa) 




demonstrated that HA fragments of 4-25 disaccharides (~ 1.6-10 kDa) were angiogenic98.  
In this study, we used an intermediate size HA fragment with an average molecular 
weight of 74 kDa (about 185 disaccharide units). Future studies will explore various size 
fragments and concentrations of HA to produce reliable SIS for consistent regenerative 
properties. 
HA was utilized for enhancing regenerative properties of SIS, since it is a sugar-based 
ECM component and has a longer shelf life than angiogenic protein molecules such as 
vascular endothelial growth factor (VEGF) or fibroblast growth factor (FGF).  Elevated 
levels of HA have been identified in the ECM of the fetus and have been correlated with 
scarless wound healing with rapid but organized collagen deposition179.  Cabrera et al. 
showed that rat wounds treated with hyaluronan associated protein-collagen complex 
healed quickly with more organized collagen as compared to untreated wounds180.  They 
concluded that manipulation of adult wound scarring might be feasible using proteins 
present in fetal skin.  HA has also been shown to inhibit platelet aggregation and cytokine 
release, which may explain, in part, the minimal inflammation and scarless healing 
characteristic of fetal dermal repair181.  In this report, we provided an approach for 
controlled incorporation and release of HA into SIS for enhanced angiogenesis that is 
required for optimal tissue regeneration. 
Angiogenesis is critical for supporting complete tissue engineering, as blood vessels 
are needed to deliver oxygen and nutrients to the new tissue and remove byproducts of 
metabolism.  Both cell models and in vivo models were used to determine the 
effectiveness of the HA-PLGA NPs modified SIS on endothelial cell growth and 




defined.  Even though the 1:1 w:w ratio of HA:PLGA showed the most significant effect 
in enhancing cell growth and angiogenesis, we decided to study the effect of the 0.5:1 
ratio in the dog bladder model. This is unfortunately one of the study limitations. The 
reason 0.5:1 was chosen because at the time of the animal study, the in vitro studies have 
not been completed yet. There was a concern that the 1:1 HA:PLGA might be very 
potent. Overgrowth or uncontrolled proliferation of vasculature may lead to arteriovenous 
malformation or even tumorigenesis.  Another concern was that the 0.2:1 might not have 
enough HA to trigger any response as determined by experiments discussed earlier. 
Therefore, although HA-PLGA at 1:1 and 0.5:1 (w:w) showed significant improvements 
in promoting endothelial cell growth and angiogenesis in CAM, we chose to utilize the 
0.5:1 (w:w) HA:PLGA ratio instead of the 1:1 (w:w) in the dog bladder augmentation 
model based on moderate angiogenesis that occurred with this ratio in the CAM model.  
Future studies are required to compare various ratios of HA and PLGA in their ability to 
promote angiogenesis and to define the most consistent and reliable biomaterial for tissue 
engineering. Furthermore, although we have chosen to utilize a dog bladder augmentation 
model to study in vivo effects of HA-PLGA-SIS, the benefits of this biomaterial will 
apply to other areas of regenerative medicine including abdominal wall reconstruction, 
nerve grafting, and skin replacement. 
Unfortunately, there were limitations in this study. One of which is failure to include 
an appropriate  proper control (PLGA NPs modified SIS) in the in vivo animal model. 
This would have allowed us to determine if the angiogenic potential of HA-PLGA NPs 
modified SIS was due to the HA alone or to the PLGA NPs alone or a combined effect. 




growth on the SIS as compared to unmodified SIS. Therefore, we cannot say that HA 
enhanced the angiogenic potential of the SIS because it might be a pure effect of the 
PLGA NPs. Another limitation was the use of HMEC-1 cells at early passages (12-14) as 
opposed to late passages (20-22) that were used earlier in similar experiments in Chapter 
2. This was evident by the fact that Genomic DNA extracted from HMEC-1 growing on 
PLGA SIS showed 2-3× cell increase as compared to the same experiments performed 
earlier with the same type of HMEC-1 cells (but a much later passage as discussed 
above). Therefore, it is very critical to use cells at early passages for similar studies. The 
experiments performed in these studies used similar passage cells for all groups per 
study. Another study limitation is the fact that there were no commercially available 
antibodies for dog tissue. We could not determine expression of HA and its receptors in a 
regenerated dog bladder. Future studies should focus on generating antibodies against 
dog tissue to validate that the results obtained could be due to delivery of exogenous HA. 
  In conclusion, the HA-PLGA NPs modified SIS supported HMEC-1 growth and 
enhanced the angiogenic potential of the newly designed biomaterial both in vitro with 
the CAM model and in vivo with the dog bladder augmentation model. We have proven 
that the incorporation of NPs into naturally derived biomaterials such as SIS can reduce 





Chapter 5 Overall Conclusion & Future Direction 
The long-term goal of this study is to introduce the utility of nanotechnology in 
biomaterials to develop a consistent off-the-shelf scaffold that can recruit and sustain a 
normally functioning endothelium that is critical in tissue regeneration.  Endothelial cells 
have an important role in the wound healing process.  A healthy vascular supply is 
critical to restore the endothelial cell signaling pathways that are altered by injury and 
disease.  It is believed that this modified biomaterial can be applied in various clinical 
scenarios where vascularization is altered. 
Heterogeneity of SIS presents a major issue for this biomaterial to produce consistent 
tissue repair and regeneration.  We demonstrated that the introduction of NPs represents a 
potential solution to improve the quality of regenerated tissues like urinary bladder using 
SIS.  Nanoparticles with size range 200-500 nm can be embedded into the SIS to reduce 
the permeability of SIS to urea. The enhanced HMEC-1 cell proliferation on PLGA NP 
modified SIS, which may result from a uniformed porous structure as compared to 
unmodified SIS, led to enhanced angiogenesis in vitro.  To take this one-step further, 
these PLGA NPs can serve as potential carriers for angiogenic factors such as HA. 
However, before delivery of exogenous HA can be performed, HA receptors must be 
available. Therefore, expression of HA and HA receptors in regenerated tissue must be 
determined. Hence, it is very important to determine antibodies that can detect HA and its 
receptors in a dog bladder model. This will validate the delivery of HA and show that in 
fact it is the interactions of exogenous HA with its receptors that are responsible for the 




We have sought to study the temporal expression of HA and its receptors in a 
regenerated animal model. Our study was the first to demonstrate changes in the 
deposition of HA and temporal expression of HA receptors during the process of rat 
urinary bladder regeneration. We showed that HA and its two major receptors, CD44 and 
LYVE-1, co-expressed in a temporal fashion. Expression of HA and HA receptors could 
be closely related to inflammatory responses, cell differentiation, angiogenesis and 
lymphangiogenesis during different phases of tissue regeneration. Further research is 
needed to determine the mechanism of expression of HA-induced bladder regeneration to 
improve the outcomes in tissue engineering. For example, to understand fully the cell 
signaling mechanism behind the effect of HA, one might look into blocking one HA 
receptor at a time and perform a western blot to determine the protein expression. We can 
also study the expression of the HA receptors after incorporation of exogenous HA. 
HA-PLGA nanoparticles were synthesized to modify even further a naturally derived 
biomaterial, SIS, for enhanced tissue regeneration.  Biodegradable PLGA NPs serve as an 
excellent vehicle for delivering biological molecules.  From in vitro to in vivo models, 
NP-modified biomaterial design has demonstrated the capacity of HA-PLGA NPs to 
enhance endothelial cell proliferation and ultimately promote angiogenesis in a pre-
clinical large animal bladder augmentation model. This newly modified SIS (HA-PLGA-
SIS) could serve as the future biomaterial needed for better tissue regeneration. As stated 
before, since species difference can be an issue (rat vs. dog), we must first show that HA 
and its receptors are available throughout the regeneration process. 
Recall that the SIS was harvested from 3-year old pigs. One avenue of exploration 




ages. Furthermore, one can explore SIS harvested from different locations of the small 
intestine within the same pig and study the effect of embedding PLGA NPs into these 
materials. It would be interesting to see if all of the above-mentioned materials would 
display the same permeability to urea, after being modified by PLGA NPs.  
Another avenue to explore is testing different sizes (molecular weights) of HA. 
Scientists do not fully understand why different sizes of HA have opposite roles nor can 
they determine a critical size or borderline.  We have shown that HA with an average 
molecular weight of 74 kDa showed promising angiogenic potential both in vitro and in 
vivo. However, further investigations need to be performed to determine the optimal size 
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AF: Angiogenic factors 
CD44: Cluster of differentiation 44 
DAB: 3,3’-Diaminobenzidine 
ddH2O: Double distilled water 
DLS: Dynamic light scattering 
ECM: Extracellular matrix 
FBS: Fetal bovine serum 
FGF: Fibroblast growth factor 
GAG: Glycosaminoglycan 
HA:  Hyaluronic acid 
HA-PLGA-SIS: SIS modified with HA-PLGA NPs 
HARE: Hyaluronic acid receptor for endocytosis 
HMEC-1: Human microvascular endothelial cells 
HRP: Horseradish peroxidase 
LYVE-1: Lymph vessel endothelial receptor 1 
MW: Molecular weight 
NPs: nanoparticles 
PBS: Phosphate buffer saline 
PDGF: Platelet derived growth factor 
PEI: poly(ethyleneimine) 
PGA: Poly(glycolic acid) 




PLGA: Poly(lactide-co-glycolide) acid also known as poly(lactic-co-glycolic) acid 
PVA: Poly(vinyl alcohol) 
RHAMM: Receptor for hyaluronic acid mediated motility 
SEM: Scanning electron microscope 
SIS: small intestinal submucosa 
TGF: Transforming growth factor 
TNE: Tris-HCl + NaCl + EDTA 
TNF: Tumor necrosis factor 
VEGF: Vascular endothelial growth factor 
VEGFR-3: Vascular endothelial growth factor receptor 3 
VPF: Vascular permeability factor 
 
